Skip to content
naulon

No retraction, correction or concern found when last checked on Oct 22, 2026.

Bioactive Molecules Released in Food by Lactic Acid Bacteria: Encrypted Peptides and Biogenic Amines

Enrica Pessione, Simona Cirrincione

Frontiers in Microbiology · 2016 · Review

doi:10.3389/fmicb.2016.00876

Abstract

Lactic acid bacteria (LAB) can produce a huge amount of bioactive compounds. Since their elective habitat is food, especially dairy but also vegetal food, it is frequent to find bioactive molecules in fermented products. Sometimes these compounds can have adverse effects on human health such as biogenic amines (tyramine and histamine), causing allergies, hypertensive crises, and headache. However, some LAB products also display benefits for the consumers. In the present review article, the main nitrogen compounds produced by LAB are considered. Besides biogenic amines derived from the amino acids tyrosine, histidine, phenylalanine, lysine, ornithine, and glutamate by decarboxylation, interesting peptides can be decrypted by the proteolytic activity of LAB. LAB proteolytic system is very efficient in releasing encrypted molecules from several proteins present in different food matrices. Alpha and beta-caseins, albumin and globulin from milk and dairy products, rubisco from spinach, beta-conglycinin from soy and gluten from cereals constitute a good source of important bioactive compounds. These encrypted peptides are able to control nutrition (mineral absorption and oxidative stress protection), metabolism (blood glucose and cholesterol lowering) cardiovascular function (antithrombotic and hypotensive action), infection (microbial inhibition and immunomodulation) and gut-brain axis (opioids and anti-opioids controlling mood and food intake). Very recent results underline the role of food-encrypted peptides in protein folding (chaperone-like molecules) as well as in cell cycle and apoptosis control, suggesting new and positive aspects of fermented food, still unexplored. In this context, the detailed (transcriptomic, proteomic, and metabolomic) characterization of LAB of food interest (as starters, biocontrol agents, nutraceuticals, and probiotics) can supply a solid evidence-based science to support beneficial effects and it is a promising approach as well to obtain functional food. The detailed knowledge of the modulation of human physiology, exploiting the health-promoting properties of fermented food, is an open field of investigation that will constitute the next challenge.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 22, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Human health is the result of a correct physiological status often resulting from the reciprocal interaction of gene-derived signals (genetics) and environment–generated information (epigenetics). Recognizing gene signals is relatively easy whereas environmental stimuli are often multiple, complex, and reciprocally interacting. Temperature, pH, redox balance, sleep, diet, drugs, and psychological status can deeply affect gene expression, metabolic pathways, and homeostasis. However, human genes and environment are not the only players: microorganisms can take part to the complex molecular cross-talk existing between external world and “self.”

Firstly, endogenous symbiont microorganisms, the so-called microbiota, can modulate gene expression, induce preferential food intake, influence pH, redox balance and the ratio between pro-inflammatory and anti-inflammatory cytokines. Briefly, control brain, metabolism, immune system, and several homeostatic routes.

Secondarily, food-derived bacteria and yeasts can exogenously affect nutritional parameters, metabolism, oxidative status, immunity, blood pressure, appetite, behavior, also controlling the endogenous microbiota by altering the ratio among saccharolytic and proteolytic species, by modulating symbionts gene expression and several other functions. Hence, all fermented food, containing living organisms, can contribute to modulation of the host physiological balance and it constitutes an opportunity to enrich the diet with new bioactive molecules finally resulting in phenotypic effects (appetite, cholesterol and blood pressure lowering, improvement of mood, antioxidant, and immune defenses) on humans. Actually, all types of modulations occur via a complex network of signals, among which proteinaceous compounds play a crucial role.

Microorganisms are able to synthesize a large number of metabolites with assessed beneficial or detrimental properties for human health. Among these, nitrogen-bearing molecules such as amino acids, amino acid derivatives and oligopeptides have received great attention since they can affect human physiology in multiple ways.

As an example, amino acid derivatives such as selenocysteines and selenomethionines, have recently been reported to be biosynthesized in both Lactobacilli and yeasts. Although selenoaminoacids are not true “bioactive compounds,” directly stimulating receptors on human cells, they can trigger effects deeply affecting human health. The bioactive role of seleno-fixing microorganisms lies in the fact that diet-derived inorganic selenium is toxic (selenate and selenite) or poorly active (elemental selenium) whereas fixed selenium forms (selenomethionines and selenocysteines) are the only bioavailable for humans. On the other hand, only bacteria and yeasts can produce seleno-amino acids from inorganic selenium. Once properly inserted into selenoproteins (i.e., glutathione peroxidase), they can counteract oxidative stress. Besides this well-known antioxidant function, there are data indicating that selenoproteins can modulate immune system and activating anabolic circuits such as thyroid hormone biosynthesis. Furthermore, epidemiological studies show an inverse correlation between selenium level in blood and cancer mortality, and laboratory experiments have shown a selenium protective effect against cancer initiation and development. In Lactobacillus reuteri exoproteome studies have demonstrated that two secreted proteins (GAPDH and Phosphoketolase) contain selenocysteines opening the way to employ this strain to supply organic bioavailable forms of selenium.

Among amino acid derivatives found in food, biogenic amines are worth of a special mention. Such compounds, although sometimes naturally present (especially in vegetal food) are often the result of the bacterial decarboxylative activity on free amino acids in food. Biogenic amines can be present in non-fermented food, like fish, due to spoilage bacteria that during protein putrefaction release free amino acids undergoing decarboxylation. E. coli can produce cadaverine from lysine and putrescine from ornithine. Proteus can produce putrescine from ornithine as a communication signal. However, also not-spoiled food, such as fermented food, can present the risk of biogenic amine accumulation. Although starters, exogenously added to perform controlled fermentations, are accurately typed to avoid any risk, autochthonous or contaminant lactic acid bacteria (LAB) can contribute to amine release. LAB are strong amine producers since they use this metabolic pathway (at the place of respiration) to both create a proton gradient and hence energy (for exhaustive review, see ) and to alkalinize the environment, very acidic since their main fermentation products are acids (lactic acid for homofermenter LAB and lactic + formic + acetic acid in heterofermenters).

Many experimental evidences demonstrate that some LAB strains also produce anti-hypertensive, anti-thrombotic, cholesterol-lowering, metal-chelating, antimicrobial, anti-oxidant, immune-modulating, chaperone-like and opioid/opioid antagonist peptides from food proteins, and they can modulate the concentration of opioid and cannabinoid receptors in the gut epithelium. The next sections will focus on some of the referred compounds and will illustrate the main effects exerted on human health.

Encrypted Bioactive Peptides

Several bioactive peptides, lacking activity when protein-encrypted but acquiring their biological effects when proteolytically released, have been shown to have health-promoting properties as anti-microbials, hypocholesterolemics, opioid and opioid antagonists, angiotensin-converting enzyme inhibitors, anti-thrombotics, immunomodulators, cytomodulators, and anti-oxidants.

The human pool of digestive proteases and peptidases can liberate food-encrypted bioactive peptides that can be absorbed by the gut and then reach peripheral organs. However, the enzymatic activity of LAB largely contribute to their release, either into the food matrix (starter or autochthonous LAB) or in the gut (endogenous microbiota or probiotics). LAB are ancient organisms adapted to an anoxic environment that never evolved the capability to biosynthesize heme and hence to have functional cytochromes, catalases, and peroxidases. They are very sensitive to oxygen and devote most of their genes to oxygen stress counteracting. Due to the limited length of the overall genome, the biosynthetic abilities of LAB are very limited especially in amino acid synthesis. Therefore, LAB evolved a complex and sophisticated proteolytic system allowing them to get amino acids from the proteins present in the external environment. A schematic representation of this system, which includes proteases, peptidases and membrane transporters, is referred in Figure 1.

LAB Proteolytic System

Extracellular protein hydrolysis into various long oligopeptides is initiated by a cell-envelope proteinase (CEP). Oligopeptides generated by this first cleavage are subsequently taken up by cells via specific transport systems and they undergo further degradation into shorter peptides (bioactive or possible precursors of bioactive compounds) and amino acids in the cytoplasm. In LAB the oligopeptide transporter system (Opp) is the main transporter, belonging to a superfamily of highly conserved ATP-binding cassette transporters. The Opp system of L. lactis transports peptides up to at least 18 residues. It should be underlined that most bioactive peptides are released into the external environment only when cells undergo autolysis, because only occasionally the longer peptides (originated by the first hydrolytic step) possess biological activity. Nevertheless, some authors reported that CEP from Lactobacillus delbrueckii subsp. lactis are suitable to liberate both metal-chelating and anti-hypertensive peptides directly from caseins and without necessity of prior cell autolysis. Maximum CEP activity was a little bit decreased by the addition of NaCl (1%) and glycerol (5%; ). However, proteolytic enzymes released by LAB proved to be very different in the different LAB species and strains, giving rise to a different pool of bioactive peptides.

Food Matrices Containing Encrypted Peptides

Lactic acid bacteria proteolytic system is suitable to produce bioactive peptides from several food proteins, especially caseins that constitute the main nitrogen substrate present in their habitat (milk and milk derivatives; ). Casein consists of four main proteins (whose ratio is about 38:11:38:13): alpha s1 casein, alpha s2 casein, beta-casein and k-casein, differing in amino acid sequence, hydropathicity index, glycosylation and phosphorylation degree. Usually, CEPs have a strong preference for hydrophobic caseins and Lactococcus CEPs have been classified into several types and subtypes depending on their substrate specificity for αS1-, β-, and κ-caseins. Casein hydrolysis can give rise mainly to opioid/anti-opioid peptides, antithrombotic and antihypertensive, immunomodulatory, mineral-binding and antimicrobial peptides easily detectable by means of chromatographic techniques after microbial food digestion.

Hydrolytic cleavage of milk whey proteins (alpha-lacto-albumine, beta-lacto-globulin, lactoferrin, and immunoglobulins) can also generate bioactive molecules, such as hypocholesterolemic peptides, which can decrease absorption and enhance fecal extrusion of cholesterol. Actually, milk whey proteins display a greater cholesterol-lowering activity than casein, in particular beta-lactoglobulin. Beta-lactoglobulin-released peptides also exhibit antioxidant and immune-modulating activity.

Bio-active molecules, especially ACE-inhibiting peptides, can also be found encrypted in bovine meat proteins, such as hemoglobin (i.e., hemorphins) and serum albumin (i.e., serorphin), collagen, elastine, fibrinogen.

However, also food of vegetal origin can be a source of bioactive peptides. In soy β-conglycinin β-subunit and in the large subunit of spinach rubisco, both antihypertensive and opioid peptides (i.e., soymorphins-5,-6, and -7, and rubiscolin-5 and -6, respectively), displaying anxiolytic effects, food intake controlling action and enhancement of memory, have been described.

A special mention needs gluten: opioid peptides (i.e., gluten exorphins A4, A5, B4, B5, and C), have been detected and characterized in wheat gluten since 1992. Some of these peptides have analgesic action on the CNS but some can also act on opioid receptors located outside the blood–brain barrier, inducing prolactin secretion. Both antihypertensive and antioxidant peptides are the result of LAB activity on wheat and other cereals. Generally, the high proline content of gluten alpha gliadins prevent hydrolysis by enzymes of the gastrointestinal tract, whereas LAB possess proline-specific peptidase systems. Alternatively, peptide degradation is achieved by the combined action of peptidase from different LAB strains simultaneously present in fermented food.

To date, LAB strains able to release bioactive peptides from food proteins, with particular reference to milk caseins, include L. helveticus CP790, L. rhamnosus GG, L. bulgaricus SS1, and L. lactis subsp. cremoris FT4. The hydrolytic ability is related to both the protein substrate, i.e., its amino acid sequence and the proteolytic enzyme panel of each microbial strain. It is possible to enhance (100-fold) the proteolytic potential of LAB by growing them in milk. Actually it has been demonstrated that peptide-rich media like MRS supplying a ready-to-eat nitrogen source are unfavorable to the induction of most proteolytic enzymes for instance those encoded by Pep N and PepX. On the other hand, CEP are able to hydrolyze caseins only after growth on skim milk but not after MRS pre-culture. Generally, lactobacilli genome encodes a larger number of proteases, peptidases, amino acid permeases, and Opp transport systems than lactococci. However, more studies on a larger number of species and strains are necessary to establish the true potential of each strain.

Finally, it is worth considering that most information on LAB proteolytic system has been referred to food matrix isolated microflora and to its action on bovine milk casein. However, endogenous or probiotic or food –derived LAB can also produce bioactive peptides from the different protein pool present in the host gut, opening interesting perspectives for improving human health. In the following paragraphs, the best known bioactive molecules generated from LAB proteases and peptidases are described.

Antimicrobial Peptides

Lactic acid bacteria proteolytic activity on caseins gives rise to small peptides displaying antimicrobial (both bactericidal and bacteriostatic) activity. Alpha s1 casein and K-casein hydrolysis gives rise to isracidin and k-casecidin, respectively. Both peptides display inhibitory action on S. aureus growth. K-casein can also originate kappacin, a long bioactive peptide active against Streptococcus mutans. This peptide, although deriving from K-casein, is phosphorylated but not glycosylated, and displays the ability to prevent bacterial adhesion to gingival mucosa and to bind enterotoxins. The alpha-s-2 casein fragment 165-203, called casocidin-I can inhibit both S. carnosus and E. coli. Lactobacillus helveticus can hydrolyze beta casein, by means of a PR4 proteinase, decrypting an antimicrobial peptide active toward several strains of Gram-positive bacteria (including S. aureus and Listeria innocua) but also against Gram-negative pathogens such as E. coli, Salmonella, Yersinia,. Homology studies revealed that this peptide has a similar length to isracidin, but a stronger hydrophobic nature (lacking positive charges) allowing a better activity on Gram-negative bacteria. Furthermore, it bears some proline residues near the C-terminal, which can prolong its half-life rendering this molecule more resistant to the peptidolytic action. The critical question concerning this peptide is that it has been decrypted from human milk but not from other caseins present in food (cow, buffalo, goat, ship).

Different peptides produced from caseins by different Lactobacillus species (L. acidophilus, L. helveticus, L. plantarum, and L. rhamnosus) and by Lactococcus lactis are active against Gram-negative rods such as Enterobacter sakazakii. An interesting antimicrobial peptide, named Lactoferricin B, having broad spectrum of action including Gram-negative and Gram-positive bacteria, yeasts and filamentous fungi, has been described as the result of the hydrolytic action on bovine lactoferrin. This cationic peptide alters membrane permeability with consequent dissipation of the proton gradient and has therefore bactericidal action. It was cloned and expressed in E. coli, showing activity against Klebsiella pneumoniae, Streptococcus Mutans, and S. aureus. Lactoferricin B is especially active toward the enterohemorrhagic strain of E. coli 0157h:7 and proved to be active also against wine-spoilage LAB such as Oenococcus oeni, Pediococcus damnosus, and Lactobacillus brevis. It is difficult to establish the real LAB potential in hydrolyzing lactoferrin. Some experiments were performed by using both microbial-derived enzymes and fermentation with proteolytic starter cultures, however, the true potential of each strain has to be experimentally proved since a great variability was observed among strains. More recently, the proteolytic activity of different LAB strains on goat milk beta casein and beta-lactoglobulin were tested. Lactococcus lactis l598, Lactobacillus lactis 1043, Streptococcus thermophilus t3D1, Dt1 and Lb. delbrueckii subsp. bulgaricus b38, b122 and b24 revealed a significant potential in producing antimicrobial peptides inhibiting S. aureus, L. monocytogenes, Listeria innocua, Enterobacter aerogenes, and Salmonella enteritidis.

Concerning the mechanism of action of such antibacterial compounds, several models have been proposed. Being amphipathic molecules, bearing a hydrophobic moiety and a strongly positively charged domain, this peptides can firstly bind to teichoic acids in Gram-positive-, or to LPS in Gram-negative bacteria and then interact with the negatively charged bacterial membranes. Most of them act as proton gradient perturbing molecules, (causing membrane depolarization like polymyxin B and colistin; ), however, some authors suggest that also removal/chelating of membrane-bound iron can affect bacterial viability. For what concern lactoferrin-derived peptides, however, it has long been established that the domains of lactoferrin involved in the antibacterial activity are different from those involved in iron binding. Complex mechanism, including inhibition of the synthesis of macromolecules as well as synergic action with host innate immunity compounds were also reported.

These antimicrobial compounds are appreciated in the food industry (especially dairy industry) as natural preservatives counteracting undesired contamination. This allows to reduce the amount of sugar and salt with excellent benefits for diabetics, obese, and hypertensive subjects. Furthermore, their stability in blood and serum render them promising infection control agents. Some of them are also good candidates to be tested for their anti-viral potential. reported the antiviral effect of bovine whey proteins, whereas very recently identified from donkey milk lactadherin a peptide displaying anti-Rotavirus activity. The actual role of LAB proteolysis in the decrypting of the antiviral potential is far to be fully elucidated. An overview of antibacterial peptides is proposed in Table 1.

Metal-Binding Peptides

Some LAB strains digest casein, releasing casein phosphopeptides (CPP) phosphorylated on Ser residues. CPP have a strong anionic character and hence are very resistant to further proteolytic degradation. They have been identified during cheese ripening due to microbial protease activity. The typical cluster is Ser(P)-Ser(P)Ser(P)-Glu-Glu, but they may contain also phosphorylated cysteines. Even if this motif is crucial for metal-binding, various phosphopeptide fractions revealed significant differences in this capability, which may be due to variant amino acid composition around the phosphorylated region. Hence, other factors can affect CPP-metal interaction, namely the total number of amino acids and the total negative charge.

It has long been established that beta and k-caseins (being poor in hydroxylated amino acids and therefore less suitable for phosphorylation) generate peptides less active in metal binding, whereas the Ser/Thr rich alpha s1 and alpha s2 caseins are the most suitable for chelating cations by means of CPP. However, alpha s1 casein-derived peptide (59–79), although bearing five phosphate groups, is less active in allowing mineral uptake by the human tumor cells HT29 than beta casein-derived peptides (1–25). Actually, besides the typical cluster sequence, specific secondary structure motifs in the bioactive peptide (such as beta-turn and loop), as well as the degree of aggregation of CPP in presence of divalent cations, are required for a correct mineral absorption.

Casein phosphopeptides can chelate up to 250 mgCa/g with a dissociation constant in the mM range, with an affinity even higher for trace elements like zinc, iron, and copper. Their mechanism of action rely on the fact that they can form soluble complexes with calcium even at alkaline pH. This results in increased absorption of calcium in the intestine, useful in the treatment of osteoporosis. Re-calcification of dental enamel and prevention of dental caries were also reported. Enhanced gut bioavailability and potential higher absorption of enzyme co-factors such as iron, zinc, copper, selenium, magnesium, and manganese, due to CPP was also described. On the other hand, controversial clinical results concerning both calcium zinc and calcium and iron absorption obtained on patients receiving CPP supplementation and controls, underline the difficulty to standardize the different supplements. Finally, calcium availability is strongly dependent on meal composition (i.e., phytates) and complex interactions between different foods ingested.

In spite of all these considerations, all described peptides may constitute interesting tools for microelements nutritional improvement. In our aging western society bone disease is the third cause of nursery care and osteoporosis is not fully controlled by a healthy lifestyle (active movement and diet; ). Therefore, calcium-enriching supplements such as CPP open new nutraceutical perspectives. However, the need to use purified and well-characterized CPP (for having a reproducible nutritional impact) highly affects the costs. Hence, the use of LAB as probiotics or food supplements to obtain functional food, especially milk based drinks and yogurts will be a promising strategy. Lactobacillus helveticus LA, is a LAB adapted to the cheese environment displaying good proteolytic activity. It can decrypt from alpha casein a peptide showing calcium-binding activity. Lactobacillus helveticus LBK16H can decrypt the tripeptides Ile-Pro-Pro and Val-Pro-Pro, both exerting anabolic effect on bones.

Antioxidant Peptides

The existence of antioxidant peptides in vegetal food (especially cereals and legumes) is a well-established concept, recently reviewed by. Marine food, such as algae and squid, as well as unusual proteins like royal jelly-derived, yak milk casein, goat milk casein, donkey milk, but also egg white lysozyme, can be a source of antioxidant peptides. Bacteria have the capability to decrypt antioxidant peptides from several food proteins. Antioxidant activities were described in fermented mussel sauce, in LAB-fermented milk whey, in fermented shrimps, during sourdough fermentation of wheat, rye, and kamut flours and in peptides derived from bovine casein after 24 h hydrolysis with Bifidobacterium longum. Antioxidant efficacy was also found in cell-free extracts of Lactobacillus plantarum isolated from traditional Chinese food (tofu and kefir) but it is rather related to pseudo catalase enzymes, exopolysaccharides and lipoteichoic acids than to bioactive peptides. Recently, mixed cultures of LAB and yeast proved to be able to produce antioxidant peptides from cow milk, however, the peptide sequences having activity were not described.

Antioxidant peptides can control both enzymatic and non-enzymatic peroxidation of fatty acids thus preventing membrane lipid peroxidation. They can act as direct radical scavengers, non-radical oxygen quenchers or metal chelators, but they also can eliminate radical precursors, hence controlling ROS damage to cells and tissues, resulting in a beneficial action on the whole organism. The redox balance between ROS and antioxidant endogenous defenses is highly impaired during chronic inflammation thus, antioxidants are essential in controlling age-related chronic degenerative diseases concerning both the cardiovascular and the central nervous system.

Natural antioxidant peptides such as GSH (Cys-Glu-Gly) or carnosine (beta-Ala-His) play important roles in radical scavenging. Antioxidant properties have been demonstrated for Tyr, Trp, His, and Lys, in particular when Tyr and Trp are in the C-terminus and the hydrophobic residues Val and Leu at the N-terminus of a peptide. Trp and Tyr behave as antioxidant molecules since their indolic and phenolic groups can act as hydrogen donors. Basic amino acids can chelate metallic ions and cysteine acts as a proton donor, thanks to its thiolic group but the highest antioxidant activity was demonstrated for the tripeptide Pro, His, His. Furthermore it was demonstrated that Leu-His-His and Pro-His-His can both act synergically with non-peptide antioxidants such as butylated hydroxyanisole.

Immunomodulatory Peptides

It is well established that some milk proteins (caseins, whey proteins, lactoferrin, lactoperoxidase) are able to control lymphocyte proliferation. Milk-derived peptides such as the C-terminus sequence of beta casein (193–209) can increase proliferation of rat lymphocytes, whereas alpha casein C-terminal hexapeptide (194–199) and beta casein fragments (63–68 and 91–93) induce macrophage maturation and phagocytosis enhancement in vitro. In agreement with these data, studies in vivo show that alpha casein-derived peptides can stimulate macrophages phagocytosis exerting a protective effect against Klebsiella pneumoniae infection in mice. Short-chain peptides from milk whey proteins also stimulate the proliferation of murine spleen lymphocytes in vitro. More detailed studies report that proliferation of human peripheral blood lymphocytes is induced by the k-casein and alpha lactalbumin fragment Tyr-Gly-Gly. Natural killer (NK) cell activity and antibody synthesis can also be enhanced by food–derived bioactive peptides. However, milk-derived peptides do not act only as simply stimulators of the immune system: immune-modulating activities including cytokines regulation and attenuation of allergic reactions has also been described.

Transferring clinical data to food is not so simple. Actually, in this scenario, LAB (especially probiotic LAB) play a very central role: beta-casein medium fermented with LAB gives rise to bioactive peptides acting on monocytes, macrophages and T helper cells, particularly with Th1-like cells. Lactobacillus paracasei hydrolyzes beta-lactoglobulin originating peptides stimulating Interleukin 10 (IL-10) production and downregulation of IL-4 and gamma interferon secretion. Casein hydrolysated by Lactobacillus rhamnosus GG displays modulating effects (both stimulation and suppression) on lymphocyte proliferation. Furthermore, casein hydrolysates from Lactobacillus rhamnosus GG can induce enhancement of anti-inflammatory cytokines from Th1 lymphocytes and a parallel decrease of pro-inflammatory cytokines and immunoglobulins produced by Th2 lymphocytes, thus controlling allergic reactions. Lactobacillus helveticus proteolysis products down-regulate cytokines production and stimulate macrophage phagocytosis and also show protective effects against E. coli O157 and Salmonella typhimurium infection. All the non-proteolytic strains of Lactobacillus helveticus failed to trigger immune system modulation. Three immune-active peptides derived both from beta casein and from alpha lactalbumin after milk fermentation with proteolytic strains of Lactobacillus helveticus were analyzed: they contain high percentage of proline histidine and lysine. Establishing how, when and in what extent proteolysis occurs in food (and in the gut) is still an open question.

Cell Cycle and Apoptosis Modulating Peptides

Milk-derived peptides, sometimes resulting from microbial proteolytic activity, can regulate cell growth, differentiation, and apoptosis. demonstrated that waste milk whey is able to induce apoptosis in CaCo2 cancer cells, but also interfere with the cell cycle (reducing the number of cells in S-phase and enhancing the number of cells in G1 phase), thus inhibiting proliferation. Cooked milk whey loose this property probably due to irreversible denaturation of proteases decrypting the peptides of interest. The endogenous microflora of milk (both starters and contaminating bacteria) seems to be the main responsible of the phenomenon observed, since fresh milk does not exhibit this behavior. Although the involved peptides were not characterized, it is very well known that some sequences such as Arg-Gly-Asp-Asp-Asp-Asp-Asp-Asp-Asp-Asp-Asp can have anti-proliferative effects on cancer cells models: the triplet Arg-Gly-Asp can account for adhesion to the extracellular matrix whereas the eight Asp residues can act intracellularly by binding chromatin. also demonstrated that normal cells are less sensitive to the apoptotic induction than malignant cells. Tumor cells apoptosis was also detected in an in vivo model in which mice were treated with milk that underwent fermentation by a highly proteolytic strain of Lactobacillus helveticus. On the contrary, the use of low-proteolytic strains did not gave satisfactory results in terms of breast cancer control in the same mice. On the other hand, not all anticancer effects of milk are related to proteolysis. It has been demonstrated that alpha lactalbumin can form a complex with oleic acid in acid conditions. This modified protein can induce apoptosis in cancer cells in vitro. Therefore, is it tempting to hypothesize that acidification caused by LAB metabolism can also contribute to these effects, and further experiments proving this will be crucial to confirm such hypothesis and opening new perspectives for cancer control. Taken together all these results suggest that it is possible to increase host defenses against tumor degeneration by using food fermented with LAB.

Opioid and Anti-opioid Peptides

These molecules constitute a promising frontier for treating both stress-related behaviors such as anxiety and depression and season-related mood disorders. They act on the appetite/satiety as well, as demonstrated by who named these molecules “nutropioids.” In general, these peptides are able to control the gut–brain axis at several levels, including gut–brain communication, brain cognitive function, and behavior. Their mechanism of action includes stimulation of receptors (K, delta, and mu) present in both the central and the peripheral nervous system and subsequent inhibition on adenylate cyclase activity. Some of these compounds are summarized in Table 2.

The best studied myorelaxant peptides are beta-casomorphins (which act on the mu receptors) and alpha s1 casein-derived peptide (which acts on the delta receptor). Their primary sequences consist of 4–10 amino acids whose N-terminal residue, (essential to trigger biological activity), is Arg in alpha s1 casein-derived peptide and Tyr in beta-casomorphins. This difference, together with the presence of six proline residues in beta-casomorphins, can account for the higher resistance to enzymatic digestion of the latter, resulting in enhanced half-life and absorption in human digestive tract. Once in blood, beta-casomorphins can reach receptors in the brain and in the peripheral tissues thus exerting a relaxing action inducing calmness and sleeping. Another interesting peptide derived from alpha s1casein is alpha-casozepine, displaying anxiolytic action but not directly interacting with the mu and delta receptors. It has been demonstrated that the biological effect is mediated by activation of serotonin and GABAA receptors, causing release of endogenous serotonin, dopamine, and GABA. Conversely, casoxins peptides (originated from k-casein hydrolysis) behave as opioid-antagonists over both the mu and k-type receptors. Due to this different physiological role, casoxins can be employed to counteract depression.

Peptides produced with the contribution of LAB protease system on dairy proteins are named exorphins and casoxins, the former having opioid–like and the latter opioid-antagonist function. However, other foods may contain opioid/anti-opioid peptides. It has long been established that wheat gluten is a good source of opioid peptides, and more recently, it has been shown that gluten exorphin B5 can enhance prolactine secretion by acting on receptors present outside the blood brain barrier. In this case, the biological effect is linked to a reduced dopaminergic tone. Soymorphins are very interesting opioid peptides acting on mu-receptors present in the gut and connected with the serotonin, dopamine, and GABA receptors systems. It was shown that soy-derived opioid peptides act as anorexigenics and also reduce gastrointestinal motility. A delta-opioid peptide called rubiscolin was decrypted from the large subunit of spinach rubisco. The rubiscolin amino acid sequence is Tyr-Pro-Leu-Asp-Leu-Phe and it displays an analgesic effect besides being involved in memory consolidation. also report anxiolytic action of this natural peptide by activation of the sigma1 and D1 dopamine receptors, when delivered orally (100 mg/Kg). The replacement of Leu3 with Ile or Met enhances by a factor four the opioid activity, whereas the replacement of Phe with Val potentiates the opioid activity more than 10-fold. The overall activity of the sequence Tyr-Pro-Met-Asp-Leu-Val is 20 times higher than the natural rubisco derivative.

Antithrombotic Peptides

Blood coagulation occurs through a complex system of proteins undergoing a sequential proteolytic cascade. These proteins include pro-enzymes such as fibrinogen that is proteolytically activated to fibrin by means of thrombin. Bovine k-casein derived oligopeptides (fragment 106–116, 11 amino acids long) named casoplatelins (or thrombin inhibitory peptides), can inhibit the binding of human fibrinogen (gamma chain) on the platelet surface receptor, due to sequence homology between fibrinogen gamma chain and K-casein. Actually, the mechanism involved in milk clotting, defined by interaction of k-casein with chymosin bear a remarkable similarity to the process involved in blood clotting, defined by interaction of fibrinogen with thrombin. As a result, they prevent aggregation of ADP-activated platelets. Also the glycopeptide present on the N-terminus of k-casein, a smaller molecule called casopiastrin, displays inhibiting activity on fibrinogen binding on the platelet membrane. Although these molecules are mainly the result of human proteolysis on milk, LAB proteolytic activity on casein can contribute to their release both in food and in vivo. Casoplatelins are present in high amounts in the gut but, after absorption, significant concentrations are still bio-available in blood thus contributing to thrombosis control in humans.

Antihypertensive Peptides

Lactobacillus helveticus, Lactobacillus delbrueckii subsp. Bulgaricus SS1, Lactobacillus delbrueckii subsp. lactis, and Lactococcus lactis subsp. cremoris FT4 can modulate blood pressure by producing angiotensin 1-converting enzyme inhibitory peptides (ACE inhibitors) from milk proteins. ACE is a carboxypeptidase converting angiotensin I (a decapeptide) into angiotensin II (an octapeptide) having a strong vasoconstrictor action. Lactobacillus delbrueckii subsp. lactis hydrolyzes both alpha s1 and beta casein (but not k-casein) by means of a cell envelope proteinase releasing antihypertensive peptides: the proteolytic activity was maximal during the logarithmic growth and addition of NaCl and glycerol prevents correct proteolysis. Casein-derived anti-hypertensive peptides are 2–6 amino acids long oligopeptides. Generally, LAB peptidases, by shortening the poly/oligopeptide chain, contribute to enhance the anti ACE potential. Actually the 6 (alpha s1 casokinin-6 = Thre-Thre-Met-Pro-Leu-Trp) and the 5 (alpha s1 casokinin-5 = Phe-Phe-Val-Ala-Pro and betacasokinin = Lys-Val-Leu-Pro-Val) amino acids long oligopeptides are less active than the tripeptides made up of Val-Pro-Pro and Ile-Pro-Pro. A very small dipeptide Tyr-Pro, proved to be effective in blood pressure control as well. The final active short peptides are resistant to both pH variations and human digestive enzymes thus opening interesting applicative perspectives.

Cholesterol-Lowering Peptides

Hypocholesterolemic peptides can be originated by beta-lactoglobulin, casein and soy proteins proteolysis. They can lower the total cholesterol of rats in vivo. Their mechanism of action probably consists in the reduction of the micellar cholesterol solubility or also to an enhanced ability to bind taurocholate. They overall action prevents cholesterol absorption by CaCo2 cells in vitro and enhances fecal steroid excretion in vivo. The sequences displaying such activities are Ile-Ile-Ala-Glu-Lys, Ala-Leu-Pro-Met-His and Gly-Leu-Asp-Ile-Gln-Lys.

Glucose-Uptake Stimulating Peptides

It has been demonstrated that dipeptides containing branched chain amino acids (Ile-Ile, Leu Leu, Ile-Leu, Leu-Ile, Ile-Val, Leu-Val, Val-Leu) can enhance glucose uptake in skeletal muscle cells, favoring glycogen synthesis and thus controlling hyperglycemia. Generally, glucose uptake by skeletal muscle cells is induced by exercize-training by means of increased expression or activity of key-signaling proteins. Branched-chain amino acids are the main nitrogen source for skeletal muscles and milk whey proteins are particularly rich in branched chain amino acids (22.3%) as compared to caseins (20.3%), soy proteins (17.5%), or wheat gluten (14.1%; ). The dipeptide Ile-Leu is the most abundant after milk whey hydrolysis. Therefore, assessing the proteolytic activity of LAB toward milk whey proteins (that constitute natural nitrogen substrates for LAB), is a promising strategy to get nutritional supplements improving health. Proteomic approaches using LC-MS-MS can be a valuable help for identifying small nutritionally relevant peptides and a new discipline, called food peptidomics, is now expanding.

Chaperone-Like Peptides

A very interesting class of protein-encrypted peptides are those displaying chaperone-mimetic action. Synthetic peptides were constructed on the model of bovine hemorphin-6, wheat gluten exorphin C, and spinach rubiscolin-5 (all opioid peptides), and their ability in refolding model proteins was investigated. The target proteins to be refolded were heat-treated or DTT-aggregated carbonic anhydrase, ADH and bovine milk alpha lactoglobulin. The results clearly indicate that the peptides are able to refold damaged proteins thus opening the way to the interesting hypothesis that food proteins, besides their nutritional role, can act as systems involved in quality control of proteins especially during stress.

Mixed Function Peptides

Some food encrypted peptides, in case decrypted by LAB proteolytic action, possess mixed function. In Table 3 are reported the peptides displaying two or more biological activities.

As an example the tripeptides Val-Pro-Pro and Ile-Pro-Pro, released from beta and K-casein by Lactobacillus helveticus are immunomodulatory and hypotensive. This effect can be explained by the fact that ACE inhibition favors bradykinin production, and bradykinin plays a crucial role in the inflammation process by stimulating macrophages and increasing lymphokines secretion by lymphocytes.

Some immunostimulatory peptides also exhibit antimicrobial features: beta-lactoglobulin-derived peptides can improve phagocytosis but also stimulate the microbial autolytic system. This is not only restricted to bacteria but also to fungi and both naturally autolyzing and non-autolyzing strains are sensitive to this effect.

It has long been established that opioid peptides such as casomorphin agonists also decrease cell proliferation by acting on somatostatin receptors. Since opioid and somatostatin receptors are present on different cells including central nervous, endocrine and immune system the action of such peptides is more complex than expected.

Several peptides are opioid and hypotensive, especially those derived from bovine milk proteins (casomorphins, lactorphins) and beta-casomorphin 7 is opioid, hypotensive, and immunomodulatory: this last function is targeted on lymphocyte proliferation that is sometimes stimulated and sometimes inhibited depending on the peptide concentration.

Lactoferricin, the lactoferrin-derived antimicrobial peptide, besides being an antibacterial, antifungal and antiviral molecule, can also control carcinogenesis by means of its anti-inflammatory and immune-modulating properties. This effect seems to be due to a positively charged region of the peptide that is very rich in tryptophan and arginine residues

The reason of these mixed functions lies in the fact that some regions in the primary structure of caseins contain overlapping peptide sequences, exerting different physiological functions. These domains, highly hydrophobic and rich in proline residues, have been defined as “strategic zones” and are resistant to proteolytic attack.

In conclusion, of this paragraph it is important to underline that not all bioactive peptides released by the combined action of LAB proteolytic system and digestive proteases in food and in the gut can be available for humans. Actually, bioactive peptides may be degraded during digestion, may be poorly absorbed and hence reach the target tissues at a concentration lower than the one necessary to exert their biological function. As far as degradation is concerned, supplying bioactive peptides by means of GRAS bacteria (like LAB are) plus protein complements is simpler than encapsulate them and this constitutes therefore a promising strategy to transport the molecules to the intestine, preventing degradation in the upper digestive tract. Efforts have been made also to assess the real in vivo absorption of bioactive peptides: blood levels of antihypertensive peptides have been quantified (by LC ESI triple) after ingestion by human volunteers but also in vitro studies measuring epithelial translocation across CaCo2 monolayers by means of ESI-LC-MS-MS can supply reasonable information about absorption. One challenging aspect of these approaches is the need of improved “omics” methods aimed to identify low- molecular weight bioactive peptides. MALDI (matrix-assisted laser desorption ionization) TOF-MS has proved to be inadequate because of matrix interference and matrix-free methods such as NALDI (nanostructure-assisted-laser desorption ionization; ) have been re-proposed.

Bioactive Amines

A number of microorganisms synthesize, as decarboxylation products of precursor amino acids, biogenic amines. In LAB, expression (by transcriptional induction) and/or activation (by catalytic modulation) of amino acid decarboxylation systems are non-essential adaptive responses to energy depletion but also strategies to counteract acid stress.

However, not all biogenic amines are bioactive molecules since most of them only act as spoilage compounds (putrescine, cadaverine) sometimes enhancing the toxicity of true bioactive molecules. On the contrary, the decarboxylation of certain amino acids, as tyrosine and histidine, can give rise to bioactive molecules (tyramine and histamine) involved in several pathogenic syndromes, more extensively described in the following paragraphs. On the other hand, not all bioactive compounds negatively affect human health: as an example, beta-phenylethylamine derived from phenylalanine or tryptamine originated from tryptophan can exert beneficial actions (such as mood control and appetite/satiety balance regulation) when administered to humans. Similarly, it has been reported that several LAB (L. bulgaricus, L. acidophilus, L. casei, L. plantarum) can synthesize melatonin, a bioactive molecule, deriving from tryptophan decarboxylation and serotonin metabolism, acting on sleep and reproductive behavior but also controlling immunity, inflammation and carcinogenesis. A particular case is the glutamate product gamma amino butyrate (GABA): this molecule can be naturally present in food but also artificially added to enhance the nutraceutical value of a certain food (GABA-tea, GABA-rice;; ) due to its relaxing action on muscles and to its overall beneficial effects on the nervous system.

Bioamines in Food

Cheese is the food most frequently associated with a too high biogenic amine content. It is very rich in free amino acids due to the desired proteolytic action performed by both bacteria and fungi during “maturation,” when colonized by decarboxylase-positive LAB (either autochthonous or contaminant bacteria) it can be a source of tyramine, histamine, putrescine, and beta-phenylethylamine. Tyramine and beta phenylethylamine are particularly abundant in food from animal origin (including fermented sausages) since these matrices are very rich in the precursor amino acids, tyrosine, and phenylalanine, used by animals to synthesize catecholamines. Both tyramine and beta-phenylethylamine are bioactive compounds whose action will be better described in the following paragraphs.

As far as fermented meat products are concerned, tyramine, cadaverine, putrescine, and histamine can be found. Poor quality processing favoring contamination is the main cause of a too high bio-amine content of meat, however starter strains possessing the capability to form biogenic amines, like Lactobacillus curvatus, have been described as well. To prevent such a risk, selection of particular starter cultures possessing either amino oxidase activity or bacteriocin synthesis capability should be taken into concern to contain the undesired consequences of spontaneous fermentations.

Other fermented foods are alcoholic beverages such as beer, ciders, and wine, that being of vegetal origin, are generally poor of aromatic amino acid precursors. At the end of alcoholic fermentation the only amino acid present in wine in significant amount is arginine (2,4 g/L): this can be converted by the arginine decarboxylase into agmatine and then putrescine, or rather be directed to the arginine deiminase pathway (ADI) generating ammonia, ornithine (generating putrescine) and carbamoyl phosphate (Figure 2). Both putrescine and ornithine are not true bioactive compounds even if they can alter the organoleptic properties of wine and enhance the toxicity of other biogenic amines. Carbamoyl phosphate can combine with ethanol in wine generating ethyl carbamate a carcinogenic molecule.

However, if the oenological procedures are not correctly performed, other bioactive amines can be generated. Actually, at the end of the alcoholic fermentation when all the grape sugars are exhausted, yeast cells die and undergo autolysis, releasing their own proteins and proteases (from lysosomes). Hence, if dead yeasts cells are not immediately separated from wine, free amino acids (from yeast proteins) become available for autochthonous LAB able to perform malolactic fermentation (MLF; ). This secondary fermentation is widely appreciated for its improvement of wine flavor, and it is usually performed by the predominant species Oenococcus oeni or, more occasionally, by other LAB species belonging to the genera Lactobacillus and Pediococcus, which may develop during the winemaking process. Unfortunately, some LAB, besides TPP-dependent-acid decarboxylases, also bear PLP-or pyruvoil-dependent amino acid decarboxylases that can generate undesired amines, depending on the precursor amino acid present at this fermentation stage. Therefore, histamine, cadaverine, tyramine, and beta-phenylethylamine (whose action will be better described in the following paragraphs) can be produced.

The total content of biogenic amines in food varies from 1 to 50 mg/Kg (alcoholic and no-alcoholic beverages, soy products) to 20–1,500 mg/Kg [sausages, cheeses; ] At high concentrations, BA are risk factors for food intoxication, while moderate levels may lead to food intolerance It is very difficult to establish a uniform maximum limit for ingested BA since their toxic effect depends on the type of BA in question. The unique BA for which the European Food Safety Authority (EFSA) has legally set maximum limits is histamine and only related to fish and fish products. Furthermore, the toxic effects exerted by amines possessing biological activity in humans, strongly depend on individual sensitivity to them. As an example, tyramine tolerance is lower in patients treated with antidepressant mono-amino-oxidase inhibitory drugs (IMAO), which interact with amino-oxidase enzymatic systems (MAO, DAO), since these patients have an impaired ability to oxidize amines. For the same reason, the toxic effects of bioactive amines in wine consumers is enhanced by the presence of ethanol, which is one of the most effective inhibitors of amine oxidases.

Factors Affecting Amines Production in LAB

When considering the risk of bioactive amine release into food, it is important to underline that maximum energy depletion and acidification occurs during the stationary growth phase. If (theoretically) LAB can be removed from food before resting, no amine accumulation takes place. This statement is supported by proteomic investigations that revealed that, in L. hilgardii, histamine production is induced only during stationary phase. On the contrary, northern blotting experiments showed activation of the HDC (histidine decarboxylase) gene already during exponential growth phase in a different L. hilgardii strain. However, the same authors clearly demonstrated an inhibitory effect of both glucose and fructose (still high during exponential growth phase) over the genes coding for HDC in L. hilgardii, O. oeni, and P. parvulus. Furthermore, in both L. hilgardii and L. brevis, it has been demonstrated that tyramine accumulation is maximal in presence of either fructose or fructose plus L-malic acid thus supporting the idea that it is not necessary to reach the stationary phase to trigger amine accumulation. Actually, also in a different bacterial model (E. faecalis) studies involving sub-proteomes profiling demonstrated a high tyramine content already in the exponential phase when sugars are not yet consumed (experiments performed in chemically defined medium having glucose as sugar carbon source; ). Therefore, the evidences are still controversial and in part related to specific amino acid/amine reaction, in part linked to a strain difference.

A further strong evidence is the fact that amine production is related to the availability of the precursor amino acid. Supplements of tyrosine in the medium can increase about 10-fold tyramine accumulation and about twofold tyrosine decarboxylase (TDC) activity in L. brevis. Similarly, in Enterococcus faecalis, TDC was found to be more abundant in the membrane extracts when the strain was exposed to free tyrosine. Histamine is biosynthesized only in presence of histidine: the cytosolic enzyme HDC was found more abundant in cells grown in histidine medium (stimulated condition) in Lactobacillus hilgardii, and Lactobacillus 30a as compared to control conditions.

The only exception to this rule seems to be the GAD enzyme that can allow GABA accumulation even in the absence of glutamate. However, the chemically defined-medium medium (CDM) used for growing L. lactis contains glutamine, so it is possible that part of it is converted to glutamate that can undergo decarboxylation to GABA. On the other hand, a transcriptional control exists since addition of glutamate can trigger a light enhance of GABA biosynthesis.

A critical concern connected with the necessity of free amino acid availability is how bacteria can get them. As far as LAB are concerned, often in the same ecological niche where they live proteins are available (cheese) or microbial autolysis (wine) generates free proteins that can undergo proteolytic breakdown by LAB.

Interestingly, other factors can affect bioactive amine production and, among these, acids (that can undergo or not a similar decarboxylative process). It has been demonstrated that L-lactic acid does not influence both histamine accumulation and HDC biosynthesis. Similarly, malate has no effect on histamine accumulation or histidine consumption. In agreement with these data, showed that tyramine production was not affected by either malate or citrate, whereas observed that both tyramine and histamine accumulation was lower during MLF and higher after it. The utilization of the amino acids tyrosine and histidine only after malate does not necessarily indicate malate inhibition, but simply that bacteria prefer utilize carbon sources before consuming nitrogen compounds.

Other factors affecting amine accumulation in food include temperature, spices and salt content, generally controlling microbial growth. The optimum growth for most amine-producing bacteria is 20–37°C. Below this temperature, the risk to find biogenic amines in food decreases. The sausage diameter as well as the addition of spices can control a too high amine content in meat: the larger the size, the higher the risk of amines due to higher water activity and lower salt content. However, NaCl not only negatively affects bacterial growth, proteolytic activity and histidine decarboxylase activity but also stimulates both tyrosine and glutamate decarboxylase (GAD) synthesis acting as operon inducer.

Histamine

The ingestion of histamine-rich food may cause heterogeneous symptoms such as diarrhea, arrhythmia, headache, and allergic syndromes such as respiratory distress (asthma), rhino-conjunctivitis, urticaria, pruritus, and flushing. Histamine is a strong hypotensive compound also acting on many receptors present in the gastro intestinal tract. Hence, high content of histamine is responsible of the toxicity of spoiled or not properly stored fish. In black carp fillets, for example, the contents of BAs remained invariable during the early stages of storage and began to increase at the later stages of storage occurs during food storage. In particular, a significantly higher concentration of histamine (132.05 mg/kg on the third day) was detected in the black carp filets stored at 20°C, indicating that this temperature favors the formation of histamine. In wines, especially red wines undergoing spontaneous MLF by LAB, are frequently responsible of these syndromes. Amino acids generating bioactive amines (histidine, tryptophan, glutamate) can be released during the, post-alcoholic fermentation, by yeasts autolysis as referred above. The concentration of free amino acids in wine is also dependent on the proteolytic activity of the strain concerned with MLF.

Tyramine

Tyramine is a bioactive molecule acting both at vascular level (hypertension, vasal-constriction) and on the central nervous system (headache). Despite it is generally assumed that histamine is the most toxic BA, a recent work reveals that unexpectedly, tyramine is more cytotoxic than histamine on an in vitro model of the human intestinal epithelium. Furthermore, the concentrations found to be toxic are commonly reached in BA-rich foods. Severe syndromes have been described in patients lacking a correct amino-oxidase activity because in treatment with mono-amino-oxidase inhibitory drugs (MAOI). MAOI are used as antidepressant because they prevent the oxidative catabolism of brain-active amines, such as dopamine, serotonin, tryptamine, and β-phenylethylamine. Unfortunately, MAO-inhibitors cannot discriminate among the different MAOs, and their overall effect results in high concentrations of tyramine that can cause hypertensive crises, brain hemorrhage and sometimes death. Since tyramine is the biogenic amine most frequently found in cheese (due to the referred high tyrosine content of dairy products) this syndrome is also called “cheese reaction.” For the reasons explained above, MAOI development has led to compounds with improved tolerability profiles compared to the initial irreversible MAOIs, particularly in regard to tyramine-induced hypertension and dietary restrictions. The huge number of non-controlled autochthonous bacteria involved in cheese manufacturing and the accidental contamination by unwanted strains during storage render cheese a risky food for tyramine ingestion, although starters are accurately typed. TDC activity has been described in several LAB strains of the genera Lactobacillus, Carnobacterium, and Leuconostoc. The enzyme from Lactobacillus brevis and Enterococcus faecalis has been fully characterized. Proteomic studies reveal the membrane location of such a protein in Enterococcus faecalis, thus confirming the high hydrophobic nature of this enzyme (previously predicted on the basis of gene analyses suggesting large hydrophobic domains but also because of the harsh procedures needed to purify it). Interestingly, Enterococcus faecalis TDC proved to be able to produce not only tyramine from tyrosine but also beta-phenylethylamine from phenylalanine.

Beta-Phenylethylamine

β-Phenylethylamine, the decarboxylation product of phenylalanine, behaves like an endogenous amphetamine. It can control appetite/satiety thus being useful to treat obesity and related syndromes as well as in weight-control diets. Like amphetamine it can also positively affect mood. However, controversial effects including insomnia, anxiety, and a MAO-blocking activity that may extend the half-life of tyramine thus potentiating its toxicity have been described. Evidence of a specific phenylalanine decarboxylase enzyme in bacteria, has been reported only for Bacillus cohnii, a species taxonomically distant from LAB. Nevertheless, both Lactobacilli and Enterococci, frequently found in fermented food, display a clear β-phenylethylamine accumulation. Originally, some authors suggested that the β-phenylethylamine found in fermented food is the result of the activity of tyrosine decarboxylating bacteria. It is interesting to underline that in mammals and in several eukaryotic cells models a low-selective aromatic L-amino acid decarboxylase (EC 4.1.1.28) exists. In bacteria, enzymatic studies proved that TDC from E. faecalis is active also toward DOPA, but not toward other amino acids like phenylalanine while Lactobacillus bears a highly tyrosine selective TDC. More recently, the presence in E. faecalis of phenylalanine-decarboxylating TDC (EC 4.1.1.25) has been clearly demonstrated by a bi-phasic kinetic of tyramine and β-phenylethylamine production. Tyrosine is consumed first and it is fully converted into tyramine (during logarithmic growth). Then phenylalanine is decarboxylated to β-phenylethylamine, although with lower conversion rate and yield. These results are consistent with a double catalytic activity of the same protein (TDC) having higher specificity for tyrosine and only low affinity for phenylalanine. On the other hand, observed β-phenylethylamine accumulation in a recombinant E. coli expressing the TDC gene of E. faecium.

GABA

γ-Aminobutyric acid is one of the bioactive amines having true positive effects on human health. It acts as a neurotransmitter in the central nervous system of most vertebrates and plays additional roles on the overall human physiology such as lowering the blood pressure in mild hypertensive patients and acting as smooth muscles relaxation system. Bacteria can produce GABA by the decarboxylation of glutamate through GAD. Glutamate and GABA act as opposite molecules having excitatory and inhibitory roles, respectively. Lactococcus lactis NCDO 2118 can obtain GABA from glutamine opportunely converted into glutamate. It has long been established that L. lactis possess only one gene encoding GAD and that this enzymes is highly specific for glutamate (apparent Km 0.51 mM). Its molecular weight is about 54 kD and it has maximal activity at pH 4.7, whereas no activity is present at neutral pH. Differences have been reported between Lactococcus lactis subsp. lactis and L. lactis subsp. cremoris: both possess gadCB genes encoding for GAD, however, one-base deletion of adenine and one-base insertion of thymine were detected in the coding region of the latter rendering it unable to synthesize a functional GAD enzyme. Lactobacilli are the best GABA-producers, however, Lactococci, Streptococci, and Bifidobacteria can synthesize GABA as well. Several strategies have been proposed to obtain high GABA amounts from cheap substrates through LAB sourdough fermentation, batch fermentation using immobilized or entrapped Lactobacillus brevis cells for the construction of functional food. To achieve maximum GABA production, temperature and pH are crucial. Nowadays, several nutraceutical preparations, such as GABA tea, GABA rice, GABA soymilk, and GABA chocolate are available, especially in Asia. GABA natural content of cacao is about 0.009%, however, this value is lower when considering the market-available chocolate also containing milk, sugar, and other ingredients. Functionalized chocolate, containing 0.28% GABA, proved to be able to lower the level of salivary chromogranin A and cortisol, thus reducing psychological stress.

Conclusion

The knowledge on how, when and where bioactive amines are produced by LAB present in fermented food will be helpful by one side to prevent food borne diseases but on the other side also to use food as a nutraceutical delivery system to control mood, appetite and smooth muscle relaxation.

The knowledge about food-encrypted peptides and their potential can offer, in the coming decades, new tools for valuable therapies for the treatment of infectious diseases as well as metabolic, nutritional and psychiatric disorders, cardiovascular diseases, allergies and cancer, as suggested by. The increasing availability of mass spectrometry facilities together with homology-based identification of potential bioactive peptide domains on protein sequences allows in silico prediction of encrypted peptides and will in the future be essential for targeting the right proteins. Several data banks are available for the bio-informatics analysis of potential bioactive peptides, especially antibacterial peptides, due to the urgent issue to face antibiotic resistance. APD2 and CAMP are databases set up to classify not only antibacterial but also antifungal and antiviral peptides. An even larger target is supplied by BIOPEP, Pep Bank, and Peptide DB, also classifying peptide hormones, growth factors and cytokines.

A new term, “nutritional peptidomics” has been proposed by to underline the importance of characterizing (mainly by mass spectrometry) food-encrypted peptides displaying health effects. These approaches allow to set up procedures to liberate the hidden bioactive molecules by means of different proteolytic enzymes (pepsin, trypsin, chymotrypsin) but also to synthesize artificial peptides displaying bioactivity. Microbial fermentation is one of the most promising strategies to generate bioactive peptides, hence genomic and proteomic characterization of new strains to predict their proteolytic profile is a challenging approach in view of obtaining functional food. As far as LAB are concerned, combining the substrate specificity and the cleavage pattern of LAB proteases can highlight the strain potential to release health-promoting molecules (or possible dangerous compounds) in food. This is a valuable strategy for selecting the right starters and to enhance the number of LAB strains to be used as food additives or probiotics. Moreover, the use of industrial by-products, such as milk whey, as growth substrates can lower the cost of functional food production and furtherly improve nutraceutical food availability.

Author Contributions

EP: Overall organization of the paper and content. SC: Figure and table management and critical reading.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 198

  1. 1.

    Abe Y. Umemura S. Sugimoto K. Hirawa N. Kato Y. Yokoyama N. (1995 ). Effect of green tea rich in γ-aminobutyric acid on blood pressure of Dahl salt-sensitive rats. Am. J. Hypertens. 8 74–79.

    Not in our library10.1016/0895-7061(94)00141-w

  2. 2.

    Alexandre H. Heintz D. Chassagne D. Guilloux-Benatier M. Charpentier C. Feuillat M. (2001 ). Protease A activity and nitrogen fractions released during alcoholic fermentation and autolysis in enological conditions. J. Ind. Microbiol. Biotechnol. 26 235–240.

    Not in our library10.1038/sj.jim.7000119

  3. 3.

    Alvarez M. A. Moreno-Arribas M. V. (2014 ). The problem of biogenic amines in fermented foods and the use of potential biogenic amine-degrading microorganisms as a solution. Trends Food Sci. Technol. 39 146–155.

    Not in our library10.1016/j.tifs.2014.07.007

  4. 4.

    Applebaum D. Sabo D. L. Fischer E. H. Morris D. R. (1975 ). Biodegradative ornithine decarboxylase of Escherichia coli. Purification, properties, and pyridoxal 5’-phosphate binding site. Biochem 14 3675–3681.

    Not in our library10.1021/bi00687a025

  5. 5.

    Arora T. Singh S. Sharma R. K. (2013 ). Probiotics: interaction with gut microbiome and antiobesity potential. Nutrition 29 591–596.

    Not in our library10.1016/j.nut.2012.07.017

  6. 6.

    Artemova N. V. Bumagina Z. M. Kasakov A. S. Shubin V. V. Gurvits B. Y. (2010 ). Opioid peptides derived from food proteins suppress aggregation and promote reactivation of partly unfolded stressed proteins. Peptides 31 332–338.

    Not in our library10.1016/j.peptides.2009.11.025

  7. 7.

    Bumagina Z. M. Kasakov A. S. Shubin V. V. Gurvits B. Y. (2009 ). Opioid peptides derived from food proteins suppress aggregation and promote reactivation of partly unfolded stressed proteins. Peptides 31 332–338.

    Not in our library10.1016/j.peptides.2009.11.025

  8. 8.

    Atanasova J. Moncheva P. Ivanova I. (2014 ). Proteolytic and antimicrobial activity of lactic acid bacteria grown in goat milk. Biotechnol. Biotechnol. Equip. 28 1073–1078.

    Not in our library10.1080/13102818.2014.971487

  9. 9.

    Aydin S. (2007 ). Ghrelin may be a universal peptide in all living organisms. Turk. J. Med. Sci. 37 123–124.

    Not in our library

  10. 10.

    Bellamy W. Takase M. Yamauchi K. Wakabayashi H. Kawase K. Tomita M. (1992 ). Identification of the bactericidal domain of lactoferrin. Biochim. Biophys. Acta 1121 130–136.

    Not in our library10.1016/0167-4838(92)90346-f

  11. 11.

    Belkaid Y. Hand T. W. (2014 ). Role of the microbiota in immunity and inflammation. Cell 157 121–139.

    Not in our library10.1016/j.cell.2014.03.011

  12. 12.

    Berrocal R. Chanton S. Juillerat M. A. Favillare B. Scherz J. C. Jost R. (1989 ). Tryptic phosphopeptides from whole casein. II. Physicochemical properties related to the solubilization of calcium. J. Dairy Res. 56 335–341.

    Not in our library10.1017/s0022029900028776

  13. 13.

    Bojsen A. Buesa J. Montava R. Kvistgaard A. S. Kongsbak M. B. Petersen T. E. (2007 ). Inhibitory activities of bovine macromolecular whey proteins on rotavirus infections in vitro and in vivo. J. Dairy Sci. 90 66–74.

    Not in our library10.3168/jds.s0022-0302(07)72609-7

  14. 14.

    Brogden K. A. (2005 ). Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol. 3 238–250.

    Not in our library10.1038/nrmicro1098

  15. 15.

    Carey N. (2012 ). The Epigenetics Revolution: How Modern Biology is rewriting Our Understanding of Genetics, Disease, and Inheritance. New York City, NY: Columbia University Press.

    Not in our library

  16. 16.

    Chabance B. Marteau P. Rambaud J. C. Migliore-Samour D. Boynard M. Perrotin P. (1998 ). Casein peptide release and passage to the blood in humans during digestion of milk or yogurt. Biochimie 80 155–165.

    Not in our library10.1016/s0300-9084(98)80022-9

  17. 17.

    Chang O. K. Seol K.-H. Jeong S.-G. Oh M.-H. Park B.-Y. Perrin C. (2013 ). Casein hydrolysis by Bifidobacterium longum KACC91563 and antioxidant activities of peptides derived therefrom. J. Dairy Sci. 96 5544–5555.

    Not in our library10.3168/jds.2013-6687

  18. 18.

    Chiba H. Yoshikawa M. (1986 ). “Biologically functional peptides from food proteins: new opioid peptides from milk proteins,” in Protein Tailoring for Food and Medical Uses eds Feeney R. E. Whitaker J. R. (New York: Marcel Dekker Inc.) 123–153.

    Not in our library

  19. 19.

    Choi S. I. Lee J. W. Park S. M. Lee M. Y. Ge J. Y. Park M. S. (2006 ). Improvement of gamma-aminobutyric acid (GABA) production using cell entrapment of Lactobacillus brevis GABA 057. J. Microbiol. Biotechnol. 16 562–568.

    Not in our library

  20. 20.

    Civra A. Giuffrida M. G. Donalisio M. Napolitano L. Takada Y. Coulson B. S. (2015 ). Identification of Equine Lactadherin-derived peptides that inhibit rotavirus infection via integrin receptor competition. J. Biol. Chem. 290 12403–12414.

    Not in our library10.1074/jbc.m114.620500

  21. 21.

    Clare D. A. Swaisgood H. E. (2000 ). Bioactive milk peptides: a prospectus. J. Dairy Sci. 83 1187–1195.

    Not in our library10.3168/jds.s0022-0302(00)74983-6

  22. 22.

    Coda R. Rizzello C. G. Pinto D. Gobbetti M. (2012 ). Selected lactic acid bacteria synthesize antioxidant peptides during sourdough fermentation of cereal flours. Appl. Environ. Microbiol. 78 1087–1096.

    Not in our library10.1128/aem.06837-11

  23. 23.

    Costantini A. Pietroniro R. Doria F. Pessione E. Garcia-Moruno E. (2013 ). Putrescine production from different amino acid precursors by lactic acid bacteria from wine and cider. Int. J. Food Microbiol. 165 11–17.

    Not in our library10.1016/j.ijfoodmicro.2013.04.011

  24. 24.

    Coton E. Torlois S. Bertrand A. Lonvaud-Funel A. (1999 ). Biogenic amines and wine lactic acid bacteria. Bullettin 816 22–34.

    Not in our library

  25. 25.

    Cross K. J. Huq N. L. Palamara J. E. Perich J. W. Reynolds E. C. (2005 ). Physicochemical characterization of casein phosphopeptide-amorphous calcium phosphate nanocomplexes. J. Biol. Chem. 280 15362–15369.

    Not in our library10.1074/jbc.m413504200

  26. 26.

    Cryan J. F. Dinan T. G. (2012 ). Mind-altering microorganisms: the impact of the gut microbiota on brain and behavior. Nat. Rev. Neurosci. 13 701–712.

    Not in our library10.1038/nrn3346

  27. 27.

    De LeBlanc A. M. Matar C. Thériault C. Perdigón G. (2005 ). Effects of milk fermented by Lactobacillus helveticus R389 on immune cells associated to mammary glands in normal and a breast cancer model. Immunobiology 210 349–358.

    Not in our library10.1016/j.imbio.2005.05.024

  28. 28.

    De Simone C. Picariello G. Mamone G. Stiuso P. Dicitore A. Vanacore D. (2008 ). Characterisation and cytomodulatory properties of peptides from Mozzarella di Bufala Campana cheese whey. J. Pept. Sci. 15 251–258.

    Not in our library10.1002/psc.1093

  29. 29.

    Delcenserie V. Martel D. Lamoureux M. Amiot J. Boutin Y. Roy D. (2008 ). Immunomodulatory effects of probiotics in the intestinal tract. Curr. Issues Mol. Biol. 10 37–54.

    Not in our library

  30. 30.

    Dhakal R. Bajpai V. K. Baek K.-H. (2012 ). Production of gaba (γ - aminobutyric acid) by microorganisms: a review. Braz. J. Microbiol. 43 1230–1241.

    Not in our library10.1590/s1517-83822012000400001

  31. 31.

    Dimitrov Z. (2009 ). Characterization of bioactive peptides with calcium-binding activity released by specially designed cheese starter. Biotechnol. Biotechnol. Equip. 23 927–930.

    Not in our library10.1080/13102818.2009.10818574

  32. 32.

    Dionysius D. A. Milne J. M. (1997 ). Antibacterial peptides of bovine lactoferrin: purification and characterization. J. Dairy Sci. 80 667–674.

    Not in our library10.3168/jds.s0022-0302(97)75985-x

  33. 33.

    Doeven M. K. Kok J. Poolman B. (2005 ). Specificity and selectivity determinants of peptide transport in Lactococcus lactis and other microorganisms. Mol. Microbiol. 57 640–649.

    Not in our library10.1111/j.1365-2958.2005.04698.x

  34. 34.

    EFSA Panel on Biological Hazards (BIOHAZ) (2011 ). Scientific Opinion on risk based control of biogenic amine formation in fermented foods. EFSA J. 9:2393

    Not in our library10.2903/j.efsa.2011.2393

  35. 35.

    Enrique M. Manzanares P. Yuste M. Martínez M. Vallés S. Marcos J. F. (2009 ). Selectivity and antimicrobial action of bovine lactoferrin derived peptides against wine lactic acid bacteria. Food Microbiol. 26 340–346.

    Not in our library10.1016/j.fm.2008.11.003

  36. 36.

    Faithong N. Benjakul S. Phatcharat S. Binsan W. (2010 ). Chemical composition and antioxidative activity of Thai traditional fermented shrimp and krill products. Food Chem. 119 133–140.

    Not in our library10.1016/j.foodchem.2009.06.056

  37. 37.

    Fanciulli G. Dettori A. Demontis M. P. Tomasi P. A. Anania V. Delitala G. (2005 ). Gluten exorphin B5 stimulates prolactin secretion through opioid receptors located outside the blood-brain barrier. Life Sci. 76 1713–1719.

    Not in our library10.1016/j.lfs.2004.09.023

  38. 38.

    Ferraretto A. Gravaghi C. Fiorilli A. Tettamanti G. (2003 ). Casein-derived bioactive phosphopeptides: role of phosphorylation and primary structure in promoting calcium uptake by HT-29 tumor cells. FEBS Lett. 551 92–98.

    Not in our library10.1016/s0014-5793(03)00741-5

  39. 39.

    Fiat A.-M. Jollès P. (1989 ). Caseins of various origins and biologically active casein peptides and oligosaccharides: structural and physiological aspects. Mol. Cell. Biochem. 87 5–30.

    Not in our library10.1007/bf00421079

  40. 40.

    FitzGerald R. J. (1998 ). Potential uses of caseinophosphopeptides. Int. Dairy J. 8 451–457.

    Not in our library10.1016/s0958-6946(98)00068-5

  41. 41.

    FitzGerald R. J. Murray B. A. (2006 ). Bioactive peptides and lactic fermentations. Int. J. Dairy Technol 59 118–125.

    Not in our library10.1111/j.1471-0307.2006.00250.x

  42. 42.

    Fukudome S. Yoshikawa M. (1992 ). Opioid peptides derived from wheat gluten: their isolation and characterization. FEBS Lett. 296 107–111.

    Not in our library10.1016/0014-5793(92)80414-c

  43. 43.

    Gagnaire V. Pierre A. Molle D. Leonil J. (1996 ). Phosphopeptides interacting with colloidal calcium phosphate isolated by tryptic hydrolysis of bovine casein micelles. J. Dairy Res. 63 405–422.

    Not in our library10.1017/s0022029900031927

  44. 44.

    Galano E. Mangiapane E. Bianga J. Palmese A. Pessione E. Szpunar J. (2013 ). Privileged incorporation of selenium as selenocysteine in Lactobacillus reuteri proteins demonstrated by selenium-specific imaging and proteomics. Mol. Cell. Proteomics 12 2196–2204.

    Not in our library10.1074/mcp.m113.027607

  45. 45.

    Galvez A. F. de Lumen B. O. (1999 ). A soybean cDNA encoding a chromatin-binding peptide inhibits mitosis of mammalian cells. Nat. Biotechnol. 17 495–500.

    Not in our library10.1038/8676

  46. 46.

    Gerez C. L. Cuezzo S. Rollán G. Font de Valdez G. (2008 ). Lactobacillus reuteri CRL 1100 as starter culture for wheat dough fermentation. Food Microbiol. 25 253–259.

    Not in our library10.1016/j.fm.2007.10.011

  47. 47.

    Gobbetti M. Minervini F. Rizzello C. G. (2004 ). Angiotensin I-converting-enzyme-inhibitory and antimicrobial bioactive peptides. Int. J. Dairy Technol. 69 5297–5305.

    Not in our library10.1111/j.1471-0307.2004.00139.x

  48. 48.

    Gobbetti M. Stepaniak L. De Angelis M. Corsetti A. Di Cagno R. (2002 ). Latent Bioactive peptides in milk proteins: proteolytic activation and significance in dairy processing. Food Sci. Nutr. 42 223–239.

    Not in our library10.1080/10408690290825538

  49. 49.

    Goodyear L. J. Kahn B. B. (1998 ). Exercise, glucose transport, and insulin sensitivity. Annu. Rev. Med. 49 235–261.

    Not in our library10.1146/annurev.med.49.1.235

  50. 50.
  51. 51.

    Gromadzińska J. Reszka E. Bruzelius K. Wasowicz W. Akesson B. (2008 ). Selenium and cancer: biomarkers of selenium status and molecular action of selenium supplements. Eur. J. Nutr. 47 29–50.

    Not in our library10.1007/s00394-008-2005-z

  52. 52.

    Guo H. Kouzuma Y. Yonekura M. (2009 ). Structures and properties of antioxidative peptides derived from royal jelly protein. Food Chem. 113 238–245.

    Not in our library10.1016/j.foodchem.2008.06.081

  53. 53.

    Hartmann R. Meisel H. (2007 ). Food-derived peptides with biological activity: from research to food applications. Curr. Opin. Biotechnol. 18 163–169.

    Not in our library10.1016/j.copbio.2007.01.013

  54. 54.

    Hatzoglou A. Bakogeorgou E. Castanas E. (1996a ). The antiproliferative effect of opioid receptor agonists on the T47D human breast cancer cell line, is partially mediated through opioid receptors. Eur. J. Pharmacol. 296 199–207.

    Not in our library10.1016/0014-2999(95)00703-2

  55. 55.

    Hatzoglou A. Bakogeorgou E. Hatzoglou C. Martin P. M. Castanas E. (1996b ). Antiproliferative and receptor binding properties of α- and β-casomorphins in the T47D human breast cancer cell line. Eur. J. Pharmacol. 310 217–223.

    Not in our library10.1016/0014-2999(96)00339-1

  56. 56.

    Hayes M. Ross R. P. Fitzgerald G. F. Hill C. Stanton C. (2006 ). Casein-derived antimicrobial peptides generated by Lactobacillus acidophilus DPC6026. Appl. Environ. Microbiol. 72 2260–2264.

    Not in our library10.1128/aem.72.3.2260-2264.2006

  57. 57.

    Hayes M. Stanton C. Fitzgerald G. F. Ross R. P. (2007a ). Putting microbes to work: dairy fermentation, cell factories and bioactive peptides. Part I: overview. Biotechnol. J. 2 426–434.

    Not in our library10.1002/biot.200600246

  58. 58.

    Hayes M. Stanton C. Fitzgerald G. F. Ross R. P. (2007b ). Putting microbes to work: dairy fermentation, cell factories and bioactive peptides. Part II: bioactive peptide functions. Biotechnol. J. 2 435–449.

    Not in our library10.1002/biot.200600246

  59. 59.

    Hébert E. M. Mamone G. Picariello G. Raya R. R. Savoy G. Ferranti P. (2008 ). Characterization of the pattern of αs1- and β-casein breakdown and release of a bioactive peptide by a cell envelope proteinase from Lactobacillus delbrueckii subsp. lactis CRL 581. Appl. Environ. Microbiol. 74 3682–3689.

    Not in our library10.1128/aem.00247-08

  60. 60.

    Hébert E. M. Raya R. R. de Giori G. S. (1999 ). Characterisation of a cell-envelope proteinase from Lactobacillus helveticus. Biotechnol. Lett. 21 831–834.

    Not in our library

  61. 61.

    Hernández-Ledesma B. Dávalos A. Bartolomé B. Amigo L. (2005 ). Preparation of antioxidant enzymatic hydrolysates from α-Lactalbumin and β-Lactoglobulin. Identification of Active Peptides by HPLC-MS/MS. J. Agric. Food Chem. 53 588–593.

    Not in our library10.1021/jf048626m

  62. 62.

    Hernández-Ledesma B. Recio I. Amigo L. (2008 ). β-Lactoglobulin as source of bioactive peptides. Amino Acids 35 257–265.

    Not in our library10.1007/s00726-007-0585-1

  63. 63.

    Hirata H. Sonoda S. Agui S. Yoshida M. Ohinata K. Yoshikawa M. (2007 ). Rubiscolin-6 a δ opioid peptide derived from spinach Rubisco, has anxiolytic effect via activating σ1 and dopamine D1 receptors. Peptides 28 1998–2003.

    Not in our library10.1016/j.peptides.2007.07.024

  64. 64.

    Hongbing F. Xiaochang L. Hui H. Song S. Qian X. Ligeng F. (2016 ). Quality changes and biogenic amines accumulation of black carp (Mylopharyngodon piceus) fillets stored at different temperatures. J. Food Prot. 79 524–586.

    Not in our library10.4315/0362-028x.jfp-15-373

  65. 65.

    Hori G. Wang M.-F. Chan Y.-C. Komtatsu T. Wong Y. Chenc T.-H. (2001 ). Soy Protein hydrolyzate with bound phospholipids reduces serum cholesterol levels in hypercholesterolemic adult male volunteers. Biosci. Biotechnol. Biochem. 65 72–78.

    Not in our library10.1271/bbb.65.72

  66. 66.

    Huang J. Mei L. Wu H. Lin D. (2007 ). Biosynthesis of γ-aminobutyric acid (GABA) using immobilized whole cells of Lactobacillus brevis. J. Microbiol. Biotechnol. 23 865–871.

    Not in our library10.1007/s11274-006-9311-5

  67. 67.

    Huang Z. Rose A. H. Hoffmann P. R. (2012 ). The role of selenium in inflammation and immunity: from molecular mechanisms to therapeutic opportunities. Antioxid. Redox. Signal. 1 16 705–743.

    Not in our library10.1089/ars.2011.4145

  68. 68.
  69. 69.

    Iwaniak A. Dziuba J. Niklewicz M. (2005 ). The BIOPEP database - a tool for the in silico method of classification of food proteins as the source of peptides with antihypertensive activity. Acta Aliment. 34 417–425.

    Not in our library10.1556/aalim.34.2005.4.9

  70. 70.

    Jensen M. P. Vogensen F. K. Ardö Y. (2009 ). Variation in caseinolytic properties of six cheese related Lactobacillus helveticus strains. Int. Dairy J. 19 661–668.

    Not in our library10.1016/j.idairyj.2009.04.001

  71. 71.

    Jiao Z. Dong Y. Chen Q. (2014 ). Ethyl carbamate in fermented beverages: presence, analytical chemistry, formation mechanism, and mitigation proposals. Compr. Rev. Food Sci. Food Saf. 13 611–626.

    Not in our library10.1111/1541-4337.12084

  72. 72.

    Kaneko K. Iwasaki M. Yoshikawa M. Ohinata K. (2010 ). Orally administered soymorphins, soy-derived opioid peptides, suppress feeding and intestinal transit via gut μ1-receptor coupled to 5-HT1A, D2 and GABAB systems. Am. J. Physiol. 299 G799–G805.

    Not in our library10.1152/ajpgi.00081.2010

  73. 73.

    Karovičová J. Kohajdová Z. (2005 ). Biogenic amines in food. Chem. Pap. 59 70–79.

    Not in our library

  74. 74.

    Kayser H. Meisel H. (1996 ). Stimulation of human peripheral blood lymphocytes by bioactive peptides derived from bovine milk proteins. FEBS Lett. 383 18–20.

    Not in our library10.1016/0014-5793(96)00207-4

  75. 75.

    Khaldi N. (2012 ). Bioinformatics approaches for identifying new therapeutic bioactive peptides in food. Funct. Foods Health Dis. 2:10.

    Not in our library

  76. 76.

    Kitts D. D. Weiler K. (2003 ). Bioactive proteins and peptides from food sources. applications of bioprocesses used in isolation and recovery. Curr. Pharm. Des. 9 1309–1323.

    Not in our library10.2174/1381612033454883

  77. 77.

    Klaenhammer T. R. Barrangou R. Logan Buck B. Azcarate-Peril M. A. Altermann E. (2005 ). Genomic features of lactic acid bacteria effecting bioprocessing and health. FEMS Microbiol. Rev. 29 393–409.

    Not in our library10.1016/j.fmrre.2005.04.007

  78. 78.

    Korhonen H. (2009 ). Milk-derived bioactive peptides: from science to applications. J. Funct. Foods 1 177–187.

    Not in our library10.1016/j.jff.2009.01.007

  79. 79.

    Korhonen H. Pihlanto A. (2003 ). A. food-derived bioactive peptides - opportunities for designing future foods. Curr. Pharm. Des. 9 1297–1308.

    Not in our library10.2174/1381612033454892

  80. 80.

    Korhonen H. Pihlanto A. (2006 ). A. Bioactive peptides: production and functionality. Int. Dairy J. 16 945–960.

    Not in our library10.1016/j.idairyj.2005.10.012

  81. 81.

    Kunji E. R. S. Mierau I. Hagting A. Poolman B. Konings W. N. (1996 ). The proteotytic systems of lactic acid bacteria. Antonie Van Leeuwenhoek 70 187–221.

    Not in our library10.1007/bf00395933

  82. 82.

    Kütt M.-L. Malbe M. Stagsted J. (2011 ). Nanostructure-assisted laser desorption/ionization (NALDI) for analysis of peptides in milk and colostrum. Agron. Res. 9 415–420.

    Not in our library

  83. 83.

    Ladero V. Calles-Enriquez M. Fernandez M. Alvarez M. A. (2010 ). Toxicological effects of dietary biogenic amines. Curr. Nutr. Food Sci. 6 145–156.

    Not in our library10.2174/157340110791233256

  84. 84.

    Lafarga T. Rai D. K. O’Connor P. Hayes M. (2015 ). A bovine fibrinogen-enriched fraction as a source of peptides with in vitro renin and angiotensin-i-converting enzyme inhibitory activities. J. Agric. Food Chem. 63 8676–8684.

    Not in our library10.1021/acs.jafc.5b03167

  85. 85.

    Laffineur E. Genetet N. Leonil J. (1996 ). Immunomodulatory activity of β-Casein permeate medium fermented by lactic acid bacteria. J. Dairy Sci. 79 2112–2120.

    Not in our library10.3168/jds.s0022-0302(96)76585-2

  86. 86.

    Lahrichi S. L. Affolter M. Zolezzi I. S. Panchaud A. (2013 ). Food peptidomics: large scale analysis of small bioactive peptides — A pilot study. J. Proteomics 88 83–91.

    Not in our library10.1016/j.jprot.2013.02.018

  87. 87.

    Lamberti C. Purrotti M. Mazzoli R. Fattori P. Barello C. Coïsson J. D. (2011 ). ADI pathway and histidine decarboxylation are reciprocally regulated in Lactobacillus hilgardii ISE 5211: proteomic evidence. Amino Acids 41 517–527.

    Not in our library10.1007/s00726-010-0781-2

  88. 88.

    Landete J. M. Pardo I. Ferrer S. (2008 ). Regulation of hdc expression and HDC activity by enological factors in lactic acid bacteria. J. Appl. Microbial. 105 1544–1551.

    Not in our library10.1111/j.1365-2672.2008.03865.x

  89. 89.

    LeBlanc J. Fliss I. Matar C. (2004 ). Induction of a humoral immune response following an Escherichia coli O157:H7 Infection with an immunomodulatory peptidic fraction derived from lactobacillus helveticus-fermented milk. Clin. Vaccine Immunol. 11 1171–1181.

    Not in our library10.1128/cdli.11.6.1171-1181.2004

  90. 90.

    Lehtonen P. (1996 ). Determination of amines and amino acids in wine - A review. Am. J. Enol. Vitic. 47 127–133.

    Not in our library

  91. 91.

    Li S. Zhao Y. Zhang L. Zhang X. Huang L. Li D. (2012 ). Antioxidant activity of Lactobacillus plantarum strains isolated from traditional Chinese fermented foods. Food Chem. 135 1914–1919.

    Not in our library10.1016/j.foodchem.2012.06.048

  92. 92.

    Li Y. Liu T.-J. He G.-Q. (2015 ). Antioxidant activity of peptides from fermented milk with mix culture of lactic acid bacteria and yeast. Adv. J. Food Sci. Technol. 7 422–427.

    Not in our library

  93. 93.

    Li Z. Jiang A. Yue T. Wang J. Wang Y. Su J. (2013 ). Purification and identification of five novel antioxidant peptides from goat milk casein hydrolysates. J. Dairy Sci. 96 4242–4251.

    Not in our library10.3168/jds.2012-6511

  94. 94.

    Lien S. Lowman H. B. (2003 ). Therapeutic peptides. Trends Biotechnol. 21 556–562.

    Not in our library10.1016/j.tibtech.2003.10.005

  95. 95.

    Linares D. M. del Rio B. Redruello B. Ladero V. Martin M. C. Fernandez M. (2016 ). Comparative analysis of the in vitro cytotoxicity of the dietary biogenic amines tyramine and histamine. Food Chem. 197 658–663.

    Not in our library10.1016/j.foodchem.2015.11.013

  96. 96.

    Lohner K. Blondelle S. E. (2005 ). Molecular mechanisms of membrane perturbation by antimicrobial peptides and the use of biophysical studies in the design of novel peptide antibiotics. Comb. Chem. High Throughput Screen. 8 241–256.

    Not in our library10.2174/1386207053764576

  97. 97.

    Lonvaud-Funel A. (1999 ). Lactic acid bacteria in the quality improvement and depreciation of wine. Antonie Van Leeuwenhoek 76 317–331.

    Not in our library

  98. 98.

    Lonvaud-Funel A. (2001 ). Biogenic amines in wines: role of lactic acid bacteria. FEMS Microbiol. Lett. 199 9–13.

    Not in our library10.1111/j.1574-6968.2001.tb10643.x

  99. 99.

    Loukas S. Varoucha D. Zioudrou C. Streaty R. A. Klee W. A. (1983 ). Opioid activities and structures of alpha-casein-derived exorphins. Biochemistry 22 4567–4573.

    Not in our library10.1021/bi00288a034

  100. 100.

    Luo H. Chen S. Ren F. Guo H. Lin S. Xu W. (2007 ). In vitro reconstitution of antimicrobial pathogen activity by expressed recombinant bovine lactoferrin N-terminal peptide in Escherichia coli. J. Dairy Res. 74 233–238.

    Not in our library10.1017/s0022029907002531

  101. 101.

    Lyte M. (2011 ). Probiotics function mechanistically as delivery vehicles for neuroactive compounds: microbial endocrinology in the design, and use of probiotics. Bioessays 33 574–581.

    Not in our library10.1002/bies.201100024

  102. 102.

    Malaguti M. Dinelli G. Leoncini E. Bregola V. Bosi S. Cicero A. F. G. (2014 ). Bioactive peptides in cereals and legumes: agronomical, biochemical and clinical aspects. Int. J. Mol. Sci. 15 21120–21135.

    Not in our library10.3390/ijms151121120

  103. 103.

    Malkoski M. Dashper S. G. O’Brien-Simpson N. M. Talbo G. H. Macris M. Cross K. J. (2001 ). Kappacin, a novel antibacterial peptide from bovine milk. Antimicrob. Agents Chemother. 45 2309–2315.

    Not in our library10.1128/aac.45.8.2309-2315.2001

  104. 104.

    Mangani S. Guerrini S. Granchi L. Vincenzini M. (2005 ). Putrescine accumulation in wine: role of Oenococcus oeni. Curr. Microbiol. 51 6–10.

    Not in our library10.1007/s00284-004-4425-1

  105. 105.

    Mangiapane E. Lamberti C. Pessione A. Galano E. Amoresano A. Pessione E. (2014a ). Selenium effects on the metabolism of a Se-metabolizing Lactobacillus reuteri: analysis of envelope-enriched and extracellular proteomes. Mol. Biosyst. 10 1272–1280.

    Not in our library10.1039/c3mb70557a

  106. 106.

    Mangiapane E. Pessione A. Pessione E. (2014b ). Selenium and selenoproteins: an overview on different biological systems. Curr. Protein Pept. Sci. 15 598–607.

    Not in our library10.2174/1389203715666140608151134

  107. 107.

    Manzotti G. Breda D. Di Gioacchino M. Burastero S. E. (2016 ). Serum diamine oxidase activity in patients with histamine intolerance. Int. J. Immunopathol. Pharmacol. 29 105–111.

    Not in our library10.1177/0394632015617170

  108. 108.

    Mao X.-Y. Cheng X. Wang X. Wu S.-J. (2011 ). Free-radical-scavenging and anti-inflammatory effect of yak milk casein before and after enzymatic hydrolysis. Food Chem. 126 484–490.

    Not in our library10.1016/j.foodchem.2010.11.025

  109. 109.

    Marcobal A. De las Rivas B. Muñoz R. (2006 ). First genetic characterization of a bacterial β-phenylethylamine biosynthetic enzyme in Enterococcus faecium RM58. FEMS Microbiol. Lett. 258 144–149.

    Not in our library10.1111/j.1574-6968.2006.00206.x

  110. 110.

    Matar C. Carlos Valdez J. Medina M. Rachid M. Perdigon G. (2001 ). Immunomodulating effects of milks fermented by Lactobacillus helveticus and its non-proteolytic variant. J. Dairy Res. 68 601–609.

    Not in our library10.1017/s0022029901005143

  111. 111.

    Mazzoli R. Lamberti C. Coisson J. D. Purrotti M. Arlorio M. Giuffrida M. G. (2009 ). Influence of ethanol, malate and arginine on histamine production of Lactobacillus hilgardii isolated from an Italian red wine. Amino Acids 36 81–89.

    Not in our library10.1007/s00726-008-0035-8

  112. 112.

    Mazzoli R. Pessione E. Dufour M. Laroute V. Giuffrida M. G. Giunta C. (2010 ). Glutamate-induced metabolic changes in Lactococcus lactis NCDO 2118 during GABA production: combined transcriptomic and proteomic analysis. Amino Acids 39 727–737.

    Not in our library10.1007/s00726-010-0507-5

  113. 113.

    McCann K. B. Shiellb B. J. Michalskib W. P. Leec A. Wanc J. Roginskia H. (2006 ). Isolation and characterization of a novel antibacterial peptide from bovine αS1-casein. Int. Dairy J. 16 316–323.

    Not in our library10.1016/j.idairyj.2005.05.005

  114. 114.

    Medina M. A. Urdiales J. L. Rodríguez-Caso C. Ramírez F. J. Sánchez-Jiménez F. (2003 ). Biogenic amines and polyamines: similar biochemistry for different physiological missions and biomedical applications. Crit. Rev. Biochem. Mol. Biol. 38 23–59.

    Not in our library10.1080/713609209

  115. 115.

    Meisel H. Bockelmann W. (1999 ). Bioactive peptides encrypted in milk proteins: proteolytic activation and thropho-functional properties. Antonie Van Leeuwenhoek 76 207–215.

    Not in our library10.1023/a:1002063805780

  116. 116.

    Meisel H. FitzGerald R. J. (2003 ). Biofunctional peptides from milk proteins: mineral binding and cytomodulatory effects. Curr. Pharm. Des. 9 1289–1295.

    Not in our library10.2174/1381612033454847

  117. 117.

    Meisel H. Olieman C. (1998 ). Estimation of calcium-binding constants of casein phosphopeptides by capillary zone electrophoresis. Anal. Chim. Acta 372 291–297.

    Not in our library10.1016/s0003-2670(98)00335-3

  118. 118.

    Mercier A. Gauthier S. F. Fliss I. (2004 ). Immunomodulating effects of whey proteins and their enzymatic digests. Int. Dairy J. 14 175–183.

    Not in our library10.1016/j.idairyj.2003.08.003

  119. 119.

    Migliore-Samour D. Floc’ha F. Jollès P. (1989 ). Biologically active casein peptides implicated in immunomodulation. J. Dairy Res. 56 357–362.

    Not in our library10.1017/s0022029900028806

  120. 120.

    Millichap J. G. Yee M. M. (2003 ). The diet factor in pediatric and adolescent migraine. Pediatr. Neurol. 28 9–15.

    Not in our library10.1016/s0887-8994(02)00466-6

  121. 121.

    Minervini F. Algaron F. Rizzello C. G. Fox P. F. Monnet V. Gobbetti M. (2003 ). Angiotensin I-converting-enzyme-inhibitory and antibacterial peptides from Lactobacillus helveticus PR4 proteinase-hydrolyzed caseins of milk from six species. Appl. Environ. Microbiol. 69 5297–5305.

    Not in our library10.1128/aem.69.9.5297-5305.2003

  122. 122.

    Minkiewicz P. Dziuba J. Michalska J. (2011 ). Bovine meat proteins as potential precursors of biologically active peptides - a computational study based on the BIOPEP database. Food Sci. Technol. Res. 1 39–45.

    Not in our library10.1177/1082013210368461

  123. 123.

    Miquel E. Farré R. (2007 ). Effects and future trends of casein phosphopeptides on zinc bioavailability. Trends Food Sci. Technol. 18 139–143.

    Not in our library10.1016/j.tifs.2006.11.004

  124. 124.

    Mizushige T. Sawashi Y. Yamada A. Kanamoto R. Ohinata K. (2013 ). Characterization of Tyr-Leu-Gly, a novel anxiolytic-like peptide released from bovine αS-casein. FASEB J. 27 2911–2917.

    Not in our library10.1096/fj.12-225474

  125. 125.

    Möller N. P. Scholz-Ahrens K. E. Roos N. Schrezenmeir J. (2008 ). Bioactive peptides and proteins from foods: indication for health effects. Eur. J. Nutr. 47 171–182.

    Not in our library10.1007/s00394-008-0710-2

  126. 126.

    Mooney C. Haslam N. J. Holton T. A. Pollastri G. Shields D. C. (2013 ). Peptide Locator: prediction of bioactive peptides in protein sequences. Bioinformatics 29 1120–1126.

    Not in our library10.1093/bioinformatics/btt103

  127. 127.

    Moreno-Arribas M. V. Polo M. C. Jourganes F. Munoz R. (2003 ). Screening of biogenic amine production by lactic acid bacteria isolated from grape must and wine. Int. J. Food Microbiol. 84 117–123.

    Not in our library10.1016/s0168-1605(02)00391-4

  128. 128.

    Moreno-Arribas V. Torlois S. Joyeux A. Bertrand A. Lonvaud Funel A. (2000 ). Isolation, properties and behaviour of tyramine-producing lactic acid bacteria from wine. J. Appl. Microbiol. 88 584–593.

    Not in our library10.1046/j.1365-2672.2000.00997.x

  129. 129.

    Morifuji M. Kanda A. Koga J. Kawanaka K. Higuchi M. (2010 ). Post-exercise carbohydrate plus whey protein hydrolysates supplementation increases skeletal muscle glycogen level in rats. Amino Acids 38 1109–1115.

    Not in our library10.1007/s00726-009-0321-0

  130. 130.

    Mullur R. Liu Y.-Y. Brent G. A. (2014 ). Thyroid hormone regulation of metabolism. Physiol. Rev. 94 355–382.

    Not in our library10.1152/physrev.00030.2013

  131. 131.

    Muro-Urista C. Alvarez-Fernandez R. Riera-Rodriguez F. Arana Cuenca A. Tellez Jurado A. (2011 ). Production and functionality of active peptides from milk. Food Sci. Technol. Int. 17 293–317.

    Not in our library10.1177/1082013211398801

  132. 132.

    Nagaoka S. Futamura Y. Miwa K. Awano T. Yamauchi K. Kanamaru Y. (2001 ). Identification of novel hypocholesterolemic peptides derived from bovine milk β-lactoglobulin. Biochem. Biophys. Res. Commun. 281 11–17.

    Not in our library10.1006/bbrc.2001.4298

  133. 133.

    Nagaoka S. Masaoka M. Zhang Q. Hasegawa M. Watanabe K. (2002 ). Egg ovomucin attenuates hypercholesterolemia in rats and inhibits cholesterol absorption in Caco-2 cells. Lipids 37 267–272.

    Not in our library10.1007/s11745-002-0890-6

  134. 134.

    Nakamura H. Takishima T. Kometani T. Yokogoshi H. (2009 ). Psychological stress-reducing effect of chocolate enriched with γ-aminobutyric acid (GABA) in humans: assessment of stress using heart rate variability and salivary chromogranin A. Int. J. Food Sci. Nutr. 60 106–113.

    Not in our library10.1080/09637480802558508

  135. 135.

    Nomura M. Kobayashi M. Ohmomo T. (2000 ). Inactivation of the glutamate decarboxylase gene in Lactococcus lactis subsp. Cremoris. Appl. Environ. Microbiol. 66 2235–2237.

    Not in our library10.1128/aem.66.5.2235-2237.2000

  136. 136.

    Nomura M. Nakajima I. Fujita Y. Kobayashi M. Kimoto H. Suzuki I. (1999 ). Lactococcus lactis contains only one glutamate decarboxylase gene. Microbiology 145 1375–1380.

    Not in our library10.1099/13500872-145-6-1375

  137. 137.

    O’Flaerty S. (2014 ). “Probiotic-mediated modulation of host gene expression,” in Interactive Probiotics ed. Pessione E. (Boca Raton, FL: CRC Press).

    Not in our library

  138. 138.

    Oh S. H. (2003 ). Stimulation of γ-aminobutyric acid synthesis activity in brown rice by a chitosan/glutamic acid germination solution and calcium/calmodulin. BMB Rep. 36 319–325.

    Not in our library10.5483/bmbrep.2003.36.3.319

  139. 139.

    Panchaud A. Affolter M. Kussman M. (2012 ). Mass spectrometry for nutritional peptidomics: how to analyze food bioactives and their health effects. J. Proteomics 75 3546–3559.

    Not in our library10.1016/j.jprot.2011.12.022

  140. 140.

    Pessione A. Lamberti C. Pessione E. (2010 ). Proteomics as a tool for studying energy metabolism in lactic acid bacteria. Mol. Biosyst. 8 1419–1430.

    Not in our library10.1039/c001948h

  141. 141.

    Pessione E. (2010 ). “Biochemical aspects of nutrition: probiotics,” in Biochemical Aspects in Human Nutrition eds Avigliano L. Rossi L. (Kerala: Transworld research network).

    Not in our library

  142. 142.

    Pessione E. (2012 ). Lactic acid bacteria contribution to gut microbiota complexity: lights and shadows. Front. Cell Infect. Microbiol. 2:86

    Not in our library10.3389/fcimb.2012.00086

  143. 143.

    Pessione E. Mazzoli R. Giuffrida M. G. Lamberti C. Garcia-Moruno E. Barello C. (2005 ). A proteomic approach to studying biogenic amine producing lactic acid bacteria. Proteomics 5 687–689.

    Not in our library10.1002/pmic.200401116

  144. 144.

    Pessione E. Pessione A. Lamberti C. Coïsson J. D. Riedel K. Mazzoli R. (2009 ). First evidence of a membrane-bound, tyramine and beta-phenylethylamine producing, tyrosine decarboxylase in Enterococcus faecalis: a two-dimensional electrophoresis proteomic study. Proteomics 9 2695–2710.

    Not in our library10.1002/pmic.200800780

  145. 145.

    Pfluger P. T. Schriever S. C. Tschöp M. H. (2012 ). Nutropioids, hedonism in the gut? Cell Metab. 16 137–139.

    Not in our library10.1016/j.cmet.2012.07.011

  146. 146.

    Piovesana S. Capriotti A. L. Cavaliere C. La Barbera G. Samperi R. Zenezini Chiozzi R. (2015 ). Peptidome characterization and bioactivity analysis of donkey milk. J. Proteomics 119 21–29.

    Not in our library10.1016/j.jprot.2015.01.020

  147. 147.

    Porto B. Mangiapane E. Pessione A. Neves M. J. Pessione E. (2015 ). Martins FS The effects of sodium selenite on the probiotic Saccharomyces cerevisiae UFMG A-905: a physiological and proteomic analysis. J. Funct. Food 17 828–836.

    Not in our library10.1016/j.jff.2015.06.048

  148. 148.

    Power O. Jakeman P. FitzGerald R. J. (2013 ). Antioxidative peptides: enzymatic production, in vitro and in vivo antioxidant activity and potential applications of milk-derived antioxidative peptides. Amino Acids 44 797–820.

    Not in our library10.1007/s00726-012-1393-9

  149. 149.

    Prioult G. Pecquet S. Fliss I. (2004 ). Allergenicity of acidic peptides from bovine β-lactoglobulin is reduced by hydrolysis with Bifidobacterium lactis NCC362 enzymes. Int. Dairy J. 15 439–448.

    Not in our library10.1016/j.idairyj.2004.09.001

  150. 150.

    Qian Z.-Y. Jollès P. Migliore-Samour D. Schoentgen F. Fiat A.-M. (1995 ). Sheep κ-casein peptides inhibit platelet aggregation. Biochim. Biophys. Acta 1244 411–417.

    Not in our library10.1016/0304-4165(95)00047-f

  151. 151.

    Rajapakse N. Mendis E. Jung W.-K. Je J.-Y. Kim S.-K. (2005a ). Purification of a radical scavenging peptide from fermented mussel sauce and its antioxidant properties. Food Res. Int. 38 175–182.

    Not in our library10.1016/j.foodres.2004.10.002

  152. 152.

    Rajapakse N. Mendisa E. Byunb H.-G. Kima S.-K. (2005b ). Purification and in vitro antioxidative effects of giant squid muscle peptides on free radical-mediated oxidative systems. J. Nutri. Biochem. 16 562–569.

    Not in our library10.1016/j.jnutbio.2005.02.005

  153. 153.

    Rao S. Sun J. Liu Y. Zeng H. Su Y. Yang Y. (2012 ). ACE inhibitory peptides and antioxidant peptides derived from in vitro digestion hydrolysate of hen egg white lysozyme. Food Chem. 135 1245–1252.

    Not in our library10.1016/j.foodchem.2012.05.059

  154. 154.

    Recsei P. A. Snell E. E. (1985 ). Pyruvoyl-dependent histidine decarboxylases. Mechanism of cleavage of the proenzyme from Lactobacillus buchneri. J. Biol. Chem. 260 2804–2806.

    Not in our library

  155. 155.

    Reynolds E. C. Cai N. J. F. Cochrane P. Shen G. D. Walker M. V. Morgan C. (2008 ). Fluoride and casein phosphopeptide-amorphous calcium phosphate. J. Dent. Res. 87 344–348.

    Not in our library10.1177/154405910808700420

  156. 156.

    Ricci-Cabello I. Herrera M. O. Artacho R. (2012 ). Possible role of milk-derived bioactive peptides in the treatment and prevention of metabolic syndrome. Nutr. Rev. 70 241–255.

    Not in our library10.1111/j.1753-4887.2011.00448.x

  157. 157.

    Rizzello C. G. Cassone A. Di Cagno R. Gobbetti M. (2008 ). Synthesis of angiotensin i-converting enzyme (ACE)-inhibitory peptides and γ-aminobutyric acid (GABA) during sourdough fermentation by selected lactic acid bacteria. J. Agric. Food Chem. 56 6936–6943.

    Not in our library10.1021/jf800512u

  158. 158.

    Roy M. K. Kuwabara Y. Hara K. Watanabe Y. Tamai Y. (2002 ). Peptides From the N-terminal End of Bovine Lactoferrin Induce Apoptosis in Human Leukemic (HL-60) Cells. J. Dairy Sci. 85 852065–852074.

    Not in our library10.3168/jds.s0022-0302(02)74284-7

  159. 159.

    Roy M. K. Watanabe Y. Tamai Y. (1999 ). Induction of apoptosis in HL-60 cells by skimmed milk digested with a proteolytic enzyme from the yeast Saccharomyces cerevisiae. J. Biosci. Bioeng. 88 426–432.

    Not in our library10.1016/s1389-1723(99)80221-7

  160. 160.

    Saavedra L. Hébert E. M. Minahk C. Ferranti P. (2013 ). An overview of “omic” analytical methods applied in bioactive peptide studies. Food Res. Int. 54 925–934.

    Not in our library10.1016/j.foodres.2013.02.034

  161. 161.

    Santos S. M. H. (1996 ). Biogenic amines: their importance in foods. Int. J. Food Microbiol. 29 213–231.

    Not in our library10.1016/0168-1605(95)00032-1

  162. 162.

    Saraswat S. Snyder B. Isailovic D. (2012 ). Quantification of HPLC-separated peptides and proteins by spectrofluorimetric detection of native fluorescence and mass spectrometry. J. Chromatogr. B 902 70–77.

    Not in our library10.1016/j.jchromb.2012.06.018

  163. 163.

    Savijoki K. Ingmer H. Varmanen P. (2006 ). Proteolytic systems of lactic acid bacteria. Appl. Microbiol. Biotechnol. 71 394–406.

    Not in our library10.1007/s00253-006-0427-1

  164. 164.

    Sessa A. Desiderio M. A. Perin A. (1984 ). Effect of acute ethanol administration on diamine oxidase activity on the upper gastrointestinal tract of rat. Alcohol. Clin. Exp. Res. 8 185–190.

    Not in our library10.1111/j.1530-0277.1984.tb05835.x

  165. 165.

    Sharma S. Singh R. Rana S. (2011 ). Bioactive peptides: a review. Intc J. BIOautomation 15 223–250.

    Not in our library

  166. 166.

    Sharon G. Garg N. Debelius J. Knight R. Dorrestein P. C. Mazmanian S. K. (2014 ). Specialized metabolites from the microbiome in health and disease. Cell Metab. 20 719–730.

    Not in our library10.1016/j.cmet.2014.10.016

  167. 167.

    Sheih I.-C. Wub T.-K. Fang T. J. (2009 ). Antioxidant properties of a new antioxidative peptide from algae protein waste hydrolysate in different oxidation systems. Bioresour. Technol. 100 3419–3425.

    Not in our library10.1016/j.biortech.2009.02.014

  168. 168.

    Shimazu S. Miklya I. (2004 ). Pharmacological studies with endogenous enhancer substances: beta phenylethylamine, tryptamine and their synthetic derivatives. Prog. Neuropsychopharmacol. Biol. Psichiatry 28 421–427.

    Not in our library10.1016/j.pnpbp.2003.11.016

  169. 169.
  170. 170.

    Singh T. K. Fox P. F. Healy A. (1997 ). Isolation and identification of further peptides in the diafiltration retentate of the water-soluble fraction of Cheddar cheese. J. Dairy Res. 64 433–443.

    Not in our library10.1017/s0022029997002227

  171. 171.

    Singh V. P. Pathak V. Verma A. K. (2012 ). Fermented meat products: organoleptic qualities and biogenic amines–a review. Am. J. Food Technol. 7 278–288.

    Not in our library10.3923/ajft.2012.278.288

  172. 172.

    Smeianov V. V. Wechter P. Broadbent J. R. Hughes J. E. Rodríguez B. T. Christensen T. K. (2007 ). Comparative high-density microarray analysis of gene expression during growth of Lactobacillus helveticus in milk versus rich culture medium. Appl. Environ. Microbiol. 73 2661–2672.

    Not in our library10.1128/aem.00005-07

  173. 173.

    Somda M. K. Savadogo A. Barro N. Thonart P. Traore A. S. (2011 ). Effect of mineral salts in fermentation process using mango residues as carbon source for bioethanol production. Asian J. Ind. Eng. 3 29–38.

    Not in our library10.3923/ajie.2011.29.38

  174. 174.

    Svensson M. Håkansson A. Mossberg A.-K. Linse S. Svanborg C. (2000 ). Conversion of α-lactalbumin to a protein inducing apoptosis. Proc. Natl. Acad. Sci. U.S.A. 97 4221–4226.

    Not in our library10.1073/pnas.97.8.4221

  175. 175.

    Takahashi M. Fukunaga H. Kaneto H. Fukudome S. Yoshikawa M. (2000 ). Behavioral and pharmacological studies on gluten exorphin a5 a newly isolated bioactive food protein fragment, in mice. Jpn. J. Pharmacol. 84 259–265.

    Not in our library10.1254/jjp.84.259

  176. 176.
  177. 177.

    Tellez A. Corrediga M. Brovkoa L. Y. Griffith M. W. (2010 ). Characterization of immune-active peptides obtained from milk fermented by Lactobacillus helveticus. J. Dairy Res. 77 129–136.

    Not in our library10.1017/s002202990999046x

  178. 178.

    Tellez A. Corredig M. Turner P. V. Morales R. Griffiths M. (2011 ). A peptidic fraction from milk fermented with Lactobacillus helveticus protects mice against Salmonella infection. Int. Dairy J. 21 607–614.

    Not in our library10.1016/j.idairyj.2011.03.011

  179. 179.

    Teucher B. Majsak-Newman G. Dainty J. R. McDonagh D. FitzGerald R. Fairweather-Tait S. J. (2006 ). Calcium absorption is not increased by caseinophosphopeptides1,2,3. Am. J. Clin. Nutr. 84 162–166.

    Not in our library10.1093/ajcn/84.1.162

  180. 180.

    Thakur N. Qureshi A. Kumar M. (2012 ). AVPpred: collection and prediction of highly effective antiviral peptides. Nucleic Acids Res. 40 W199–W204.

    Not in our library10.1093/nar/gks450

  181. 181.

    Thomas S. Karnik S. Barai R. S. Jayaraman V. K. Idicula-Thomas S. (2010 ). CAMP: a useful resource for research on antimicrobial peptides. Nucleic Acids Res. 38 D774–D780.

    Not in our library10.1093/nar/gkp1021

  182. 182.

    Tsai J. S. Lin Y. S. Pan B. S. Chen T. J. (2006 ). Antihypertensive peptides and γ-aminobutyric acid from prozyme 6 facilitated lactic acid bacteria fermentation of soymilk. Process Biochem. 41 1282–1288.

    Not in our library10.1016/j.procbio.2005.12.026

  183. 183.

    Ulvatne H. Samuelsen Ø. Haukland H. H. Krämer M. Vorland L. H. (2004 ). Lactoferricin B inhibits bacterial macromolecular synthesis in Escherichia coli and Bacillus subtilis. FEMS Microbiol. 237 377–384.

    Not in our library10.1111/j.1574-6968.2004.tb09720.x

  184. 184.

    van Platerink C. J. Janssen H.-G. M. Horsten R. Haverkamp J. (2006 ). Quantification of ACE inhibiting peptides in human plasma using high performance liquid chromatography–mass spectrometry. J. Chromatogr. B 830 151–157.

    Not in our library10.1016/j.jchromb.2005.10.036

  185. 185.

    Virtanen T. Pihlanto A. Akkanen S. Korhonen H. (2007 ). Development of antioxidant activity in milk whey during fermentation with lactic acid bacteria. J. Appl. Microbiol. 102 106–115.

    Not in our library10.1111/j.1365-2672.2006.03072.x

  186. 186.

    Visick K. L. Fuqua C. (2005 ). Decoding microbial chatter: cell-cell communication in bacteria. J. Bacteriol. 187 5507–5519.

    Not in our library10.1128/jb.187.16.5507-5519.2005

  187. 187.

    Vorland L. H. (1999 ). Lactoferrin: a multifunctional glycoprotein. APMIS 107 971–981.

    Not in our library10.1111/j.1699-0463.1999.tb01499.x

  188. 188.

    Wakai T. Yamamoto N. (2012 ). “Antihypertensive peptides specific to Lactobacillus helveticus fermented milk,” in Biotechnology – Molecular Studies and Novel Applications for Improved Quality of Human Life, Biochemistry, Genetics and Molecular Biology ed. Sammour R. H. (Rijeka: InTech) 159–172.

    Not in our library

  189. 189.

    Wang G. Li X. Wang Z. (2009 ). APD2: the updated antimicrobial peptide database and its application in peptide design. Nucleic. Acids Res. 37(Suppl. 1) D933–D937.

    Not in our library10.1093/nar/gkn823

  190. 190.

    Wei G. S. Jackson J. L. Hatzigeorgiou C. Tofferi J. K. (2003 ). Osteoporosis management in the new millennium. Prim. Care 30 711–741.

    Not in our library10.1016/s0095-4543(03)00090-3

  191. 191.

    Yamamoto N. Maeno M. Takano T. (1999 ). Purification and characterization of an antihypertensive peptide from a yogurt-like product fermented by Lactobacillus helveticus CPN4. J. Dairy Sci. 82 1388–1393.

    Not in our library10.3168/jds.s0022-0302(99)75364-6

  192. 192.

    Yanez M. Padin J. F. Arranz-Tagarro J. A. Camina M. Laguna R. (2012 ). History and therapeutic use of MAO-A inhibitors: a historical perspective of mao-a inhibitors as antidepressant drug. Curr. Top. Med. Chem. 12 2275–2282.

    Not in our library10.2174/156802612805220011

  193. 193.

    Yang S. Yunden J. Sonoda S. Doyama N. Lipkowski A. W. Kawamura Y. (2001 ). Rubiscolin, a δ selective opioid peptide derived from plant Rubisco. FEBS Lett. 509 213–217.

    Not in our library10.1016/s0014-5793(01)03042-3

  194. 194.

    Yang S. Kawamura Y. Yoshikawa M. (2003 ). Effect of rubiscolin, a δ opioid peptide derived from Rubisco, on memory consolidation. Peptides 24 325–328.

    Not in our library10.1016/s0196-9781(03)00044-5

  195. 195.

    Yang Y. Marczak E. D. Yokoo M. Usui H. Yoshikawa M. (2003 ). Isolation and antihypertensive effect of angiotensin i-converting enzyme (ace) inhibitory peptides from spinach rubisco. J. Agric. Food Chem. 51 4897–4902.

    Not in our library10.1021/jf026186y

  196. 196.

    Zambrowicz A. Timmer M. Polanowski A. Lubec G. Trziszka T. (2013 ). Manufacturing of peptides exhibiting biological activity. Amino Acids 44 315–320.

    Not in our library10.1007/s00726-012-1379-7

  197. 197.

    Zhang H. Hu C. A. Kovacs-Nolan J. Mine Y. (2015 ). Bioactive dietary peptides and amino acids in inflammatory bowel disease. Amino Acids 47 2127–2141.

    Not in our library10.1007/s00726-014-1886-9

  198. 198.

    Zucht H.-D. Raida M. Adermann K. Mägert H.-J. Forssmann W. G. (1995 ). Casocidin-I: a casein-αs2 derived peptide exhibits antibacterial activity. FEBS Lett. 372 185–188.

    Not in our library10.1016/0014-5793(95)00974-e

Cited by papers we hold 5

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.